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During the last decade, transient mammalian cell transfection technology has become wide 
spread and accepted for the fast expression (a matter of weeks) of different recombinant 
proteins, for both pharmaceutical application and research development. The development of a 
robust, scalable, transient protein production platform based on fundamental knowledge of this 
complex process is an essential task. Strategies to optimise and develop transient transfection 
aim to improve the scalability and to extend production time via repeated transfection. 
Although polyethylenimine (PEI) is one of the most studied transient transfection mediating 
agents, many open questions still exist concerning its mechanism, toxicity and transfection 
efficiency; this lack of knowledges hinders the production of large amounts of proteins in 
comparsion to stable cell lines. 
In the present work, cell viability and transfection efficiency are the most important response 
parameters evaluated to study such fundamental processes. Transfection efficiency has been 
investigated by transfecting a plasmid-expressing green fluorescent protein (GFP) into the 
CHO-K1 cell which can easily be detected and quantitatively measured. CHOMACS CD 
medium supports cultivation of a high transfected cell density of about 10-18 million cells per 
mL with a viability of over 80%, which elucidates a transfection culture volume of up to 12.5 
mL in a Tubespin®50 bioreactor and in small shake flasks. Several conditions for transfection 
efficiency (TE) have been explored and guided by a design of experiment approach (DoE). A 
high TE of 70% combined with a high cell viability of over 95%, and an extended expression 
time of 120 hours post-transfection, (hpt) have been achieved through a modified repeated 
transient transfection strategy utilizing a low amount of 6 µg pDNA:30 µg PEI for 10 million 
cells per mL.  
Through this optimization, transforming growth factor (TGF-β1) tagged with a tryptophan label 
and a Strep-tag was successfully expressed in CHO-K1 cells. The total purified volumetric 
yield of TGF-β1 from culture supernatant was about 27 µg/mL. The bioactivity of this mature 
TGF-β1 exhibited the same extent of inhibition effect on A549 epithelial cell growth as the 
commercial one. Fluorescence spectra reveal a direct increase in fluorescence intensity 
correlated with purified protein concentration. This would represent an ideal application of 2D-
fluorescence spectroscopy for monitoring the protein productivity process.  
 








Technologien zur transienten Transfektion von Säugetierzellen zur Expression rekombinanter 
Proteine haben im vergangenen Jahrzehnt sowohl für die pharmazeutische Anwendung als auch 
für Forschung und Entwicklung an großer Bedeutung gewonnen. Die Entwicklung einer 
robusten, skalierbaren Transfektionsplatform ist dabei die Grundlage für qualitativ hochwertige 
Produkte und reproduzierbare Bioprozesse. Die Transfektion mit Polyethylenimin (PEI) ist die 
bisher am besten untersuchte Methode. Trotz des großen Aufwands, der in den vergangenen 
Jahren betrieben wurde, um die Zusammenhänge der chemischen Transfektion zu verstehen, 
blieben bisher viele Fragen offen, die sich beispielsweise mit Toxizität, Wirkmechanismen und 
Transfektionseffizienz beschäftigen. Dies ist einer der Gründe, warum pharmazeutische 
Wirkstoffe derzeit ausschließlich mit stabilen Zelllinien produziert werden.   
Der Fokus dieser Arbeit liegt darin zu untersuchen, welche Versuchsparameter sich auf die 
Zellviabilität nach Transfektion und die Transfektionseffizienz (TE) auswirken und die 
Wirkzusammenhänge zu verstehen. Zur Untersuchung der TE wurde eine CHO-K1 Zelllinie 
mit einem Plasmid zur Expression von grün fluoreszierendem Protein (GFP) transfiziert und 
die TE über das Fluoreszenzsignal verfolgt. Die Versuche wurden in Tubespin®50 
Bioreaktoren mit 12,5 mL Arbeitsvolumen sowie in 125 mL Schüttelkolben mit einem 
Arbeitsvolumen von 25 mL durchgeführt. Es wurden sukzessive DoE Experimente 
durchgeführt um die Einflüsse verschiedener Versuchsparameter quantitativ zu bestimmen. Bei 
einer Zellviabilität von über 95% wurden Expressionszeiten von über 120 h und TE von über 
70% erreicht.  
Außerdem wurde eine bereits bestehende Methode zur mehrfachen, wiederholten Transfektion 
einer CHO-K1 Zelllinie zur Expression von TGF-β1 (transforming growth factor) in der CHO-
K1 Zelllinie optimiert. Dabei wurden wesentlich geringere Mengen an PEI und Plasmid-DNA 
verwendet. Der Inhibierungseffekt auf das Zellwachstum ist dabei ebenso hoch wie bei einem 
kommerziellen Vergleichsprodukt. Die Ausbeute an aufgereinigtem Produkt lag dabei bei 27 
µg/mL. Mithilfe eines Tryptophan-Tags konnte die Produktbildung mithilfe von 
Fluoreszenzspektroskopie online verfolgt werden. Dabei korrelierte die Fluoreszenzintensität 
direkt mit der Konzentration an aufgereinigtem TGF-β1.  
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The growing worldwide demand for therapeutic recombinant proteins has created intense 
interest in the establishment of several mammalian protein production platforms. A fast tool to 
meet this growing need is necessary for these platforms and an important development goal. 
Global sales in these market segments exceeds US $120 billion per year 1. In addition, more 
than 50% of all biopharmaceutical products on the market are produced through mammalian 
cell protein expression systems 2. 
Normally, recombinant protein expression requires the introduction of foreign DNA into a host 
cell, a process known as transformation when applied to prokaryotes, and transfection when 
applied to eukaryotic cells. The biotechnology and pharmaceutical industry sectors rely heavily 
on mammalian cell culture as the bioproduction system to produce such proteins with 
glycosylation patterns similar to those of human proteins. The most widely used host 
mammalian cells for producing various kinds of protein are Chinese hamster ovary (CHO) 
cells, human embryonic kidney (HEK 293) cells, baby hamster kidney (BHK) cells and mouse 
myeloma cells, including NS0 and Sp2/0 cells 2–4. CHO cells are one of the most prominent 
mammalian cells used for expression of biopharmaceutical proteins since 1957 5. The 
pharmaceutical industry prefers to use CHO cell lines because of its well-known cell system 6.  
To date, the standard approach to supply the market with recombinant proteins is a genetically 
engineered stable transfection cell line. The recombinant gene is integrated into the host’s 
genome followed by screening and selection of high producing clones 3. The establishment of 
highly stable producer cells takes a long time – i.e. between 6 to 12 months. Recombinant 
protein expression by transient transfection of a mammalian cell line is called transient gene 
expression (TGE), a system that allows the rapid production of milligram to multigram 
quantities of protein, up to 100s of liters, in a short time frame (days to weeks) 7–9.  
This TGE system is a promising means of producing of a wide range of proteins, including 
kinases, receptors, and enzymes in as short a time as one week. Polyethylenimine (PEI) is 
considered the most common transfection reagent to achieve transient transfection flexibly and 
economically 10. Transfection criteria, for both transfection reagent and cell line are necessary 
not only for transient transfection in protein expression, but also for establishing scalable 
transient production processes. In addition, several critical parameters need to be carefully 
optimized in order to obtain reproducible and highly efficient transfections. These factors 
include media type and vector design, as well as continuous basal variables such as cells, 
plasmid DNA and PEI. Also, process design variables such as scale, temperature, osmolality 





an efficient and rapid protein expression platform are crucial to support early drug development 
or novel recombinant protein expression which is required for structural biology and therapy. 
1.1. Aim and objectives 
In this thesis, I study transient protein expression technology, with the aim to achieve higher 
and reproducible protein yields. This goal requires optimization of the gene delivery method to 
be more efficient, simpler, higher yielding and scalable at an affordable cost. Plasmid Enhanced 
Green Fluorescence Protein (pEGFP-N1) is used as a model. This plasmid, expressing green 
fluorescence protein (GFP), and the linear polyethylenimine (PEI) polymer as the transfection 
reagent to deliver the plasmid for the CHO-K1 host cell line, are the focus of this research 
work. The results of this model can be applied to other recombinant proteins for the evaluation 
of established transient transfection systems. The goal of this study was extended to include 
production of transforming growth factor beta-1 (TGF-ß1) on a lab scale using the TGF-ß1 
plasmid. This plasmid encodes a fusion protein with a Strep-tag and fluorescent tag, which 
provides an easier way to purify protein and monitor it offline, respectively.  
There are three major objectives in achieving this aim. They are as follows: 
 Optimization of GFP transient transfection. 
A.  Independent study of transfection parameters 
1) Media-related factors, such as media type, media exchange, and media osmolality. 
2) Cell culture-related factors, like pre-culture age, pre-culture cell density, and cell 
density at transfection time.  
B. Interaction study of transfection parameters using DoE approach 
1) Cell density, PEI and pDNA amount 
2) PEI and pDNA amount 
C.  Repeated transient transfection process one more time to improve transfection 
efficiency 
D. Physicochemical properties of pDNA/PEI polyplex nano-particles 
1) Nanotracking particle size formation dynamics analysis 
2) Imaging analysis of pDNA/PEI polyplex  
 Scalability of transient transfection protocol. From 1 ml to 12.5 mL in Tubespin 
bioreactor®50 and small shake flasks. 
 Transient expression of TGF-ß1 in shake flasks 
1) TGF-ß1 purification, detection and quantification 




2. Theoretical Background 
There is no doubt that the production of recombinant protein is an important issue for 
biotechnology research, bioprocess development and industry. The traditional methods for 
down-streaming amounts of functional protein from large amounts of animal or plant tissue are 
ineffective from an economic point of view. With advances in molecular biology and the 
science of gene-to-protein, it becomes easier to construct a plasmid with the desired gene and 
express it through an appropriate cell host mechanism. The following theoretical background 
discusses the issues involved in obtaining recombinant proteins. 
2.1. Recombinant protein production host systems 
Escherichia coli (E.coli) is the most widely used host for commercial recombinant protein 
production. It has the capacity for high-level protein expression and grows rapidly on 
inexpensive media. Therefore E.coli would be the first choice as a host due to its relatively 
simple, well-established cultivation requirements. The bacterial production is however defined 
by the limited capability of E.coli to form a recombinant protein with accurate quaternary 
protein folding structures and has a limited capacity with regard to post-translational 
modifications such as glycosylation, amidation, acetylation and phosphorylation. In addition, it 
often forms insoluble aggregates (inclusion bodies) or aggregates with low solubility 12–14. 
Another promising host for recombinant protein production is yeast, including Saccharomyces 
cerevisiae, Pichia pastoris and Hansenula polymorpha. Many eukaryotic post-translational 
modifications can be performed with yeasts, such as glycosylation, disulfide bond formation 
and proteolytic processing. However, other modifications, such as prolyl-hydroxylation and 
amidation as well as some types of phosphorylation and glycosylation are not possible with 
yeasts 15–17. In contrast, mammalian cells can be used to perform complex post-translational 
modifications of recombinant proteins 18. Furthermore, the chaperone system of mammalian 
cells ensures that proteins are secreted in a correctly folded manner 19. However, differences in 
glycosylation and post-translation patterns between different mammalian cell lines are also 
problematic 20. The process is very expensive with poor secretion in comparison to the other 
hosts mentioned here.  
The filamentous fungi expression host system, particularly with Aspergillus spp., and 
Trichoderma reesei, provide a high level secretion of heterologous proteins at low cost, though 
our limited understanding (compared to bacteria) of the complex physiology of filamentous 
fungi, and significant differences in glycosylation compared to mammalian cells, have hindered 
this technology up to now 21–23. Recombinant baculovirus-insect cell expression systems are 
able to produce recombinant proteins with more complex post-translational modifications 




associated with the eukaryotic system. Because in insect cells, signal peptides are cleaved as in 
mammalian cells, disulfide bonds are formed in the endoplasm reticulum and pro-protein-
converting enzymes are available for proteolytic processing. Glycosylation in insect cells is not 
identical to that in mammalian cells. This can influence protein solubility, half-life, activity and 
interactions with other molecules 20,24,25. 
While one single perfect host for all proteins does not exist, bacteria remain attractive hosts for 
producing simple proteins. For proteins that require glycosylation, mammalian cells, fungi, or 
the baculovirus system are used.  
In general, the mammalian cell host has the advantage in mimicking human glycosylation with 
direct application of the produced protein. Therefore, it represents a good host for functional 
recombinant protein production. In particular, Chinese hamster ovary (CHO) cells are the most 
commonly used mammalian cell host as they provide about 50% of the therapeutic protein 
market 26. 
2.2. Transfection methods mediate recombinant protein expression 
After selection of the suitable protein expression host for the target protein expression plasmid, 
the transfection method to deliver this plasmid to the host cell is an important issue. Many 
transfection methods have been developed to transfer genetic material into a host cell. These 
include virally, physically, and chemically mediated transfection methods. Each method should 
be compatible with the cell type and purpose. Method types, application, and advantages and 
disadvantages have been reviewed by Jin and Al-Dosari 27,28. Some methods are preferred to 
make stable transfections while others for transient transfection. Techniques and main 
difference between the two transfection systems are described in Figure 1.  
 
 
Figure 1: Difference between transient and stable transfection systems 29.  
With transient transfection, the genetic material transfers until step B and is not integrated to the cell 
chromosome (remains in episomal form). Thus, the transfected cells lose the genetic material within a 
short time. It is chemical- or electroporation-based. With stable transfection, the genetic material transfers 





Viral vector transfection involves modification of the viral genomes by deleting some areas of 
their genomes so that their replication becomes deranged; but it has to overcome genotoxicity 
and immunogenicity challenges 30. Physical methods introduce isolated DNA into the nucleus 
of single or multiple target cells. These methods are less dependent on cell type and condition 31 
and are therefore preferred for single cell stable transfection. These physical methods are based 
on achieving transient penetration into the cell membrane by mechanical, electrical, ultrasonic, 
hydrodynamic, or laser-based energy so that “naked DNA” in media enters into the targeted 
cells. Chemical systems are more common than physical methods. They are easy to use and 
effective for transfecting suspension cells and adherent cell tissues, but have to overcome the 
variability in transfection efficiency by cell type or condition. These chemical methods include 
compaction of negatively charged nucleic acid by cationic liposome/micelle or cationic 
polymers constitute nano-particles called lipoplex and polyplex, respectively. 
While all these viral and non-viral gene delivery systems have been developed in the last three 
decades, no delivery system has been designed that can be applied in gene delivery of all kinds 
of cell types in vitro and in vivo with no limitation and side effects 32. 
Chemical transfection methods enable research and development efforts to combine low 
toxicity with high transfection efficiencies, particularly with linear polyethylenimine (L-PEI) 25 
kDa molecular weight 33. The polyethylenimine cationic polymer introduced by Boussif 34 has 
become the gold standard of non-viral gene delivery in mediating transient transfection. 
Recently, application of this polyethylenimine for various protein productions in HEK-293 and 
CHO suspension cells has been reviewed by Hacker 35. The more recent study suggests that 
other higher molecular weights of linear PEI, such as 40 kDa PEI, are better for obtaining 
optimal transient protein production in both cell lines than 25 kDa PEI 36, while the lower 
molecular weight of PEI 1.8 kDa has low transfection efficiency compare to L-PEI 25 KDa 37. 
In this study linear 25 kDa PEI was used to mediate transient transfection in CHO-K1 
suspension cell line because of its successful track record in transient gene expression 
approaches 38,39. 
2.2.1. Transfection efficiency 
Transfection efficiency (TE) is a very efficient response parameter to evaluate the effectiveness 
of a transfection method for the transfer of genetic material into the host cells with minimal 
toxicity. TE determines the percentage of transfected cells in the population, either visually by 
fluorescence microscopy or quantitatively by flow cytometry. Transfection efficiency is usually 
monitored either by green fluorescence proteins (GFP) which express cytosolic fluorescent 
protein and can easily detect positively expressed cells or by luciferase reporter genes which 




produce bioluminescence in the presence of luciferin. Protein yield is directly dependent on the 
transfection efficiency 40 and post-transfection time. Improvement in the transfection efficiency 
is one of the most important research objectives. Therefore, all considered transfection methods 
should have a high transfection efficiency, low cell toxicity and be easily reproducible 41. 
The linear 25 kDa polyethylenimine chemical transfection method was found to produce cost 
effective transfection efficiency with other transfection reagents of Lipofectamine® 2000, 
TransIT-PRO® ExGen 500 and Effectene in CHO cells 42,43.  
An optimal level of GFP transfection efficiency has been reported for CHO cells between 50-
72% 35,39,44 depending on cell type suspension or adherent and media condition. The cell cycle 
as described in Figure 2 45 at S phase increases the transfection efficiency level, and, protein 
productivity increases by arresting the cells at G2/M phase 46.  
 
Figure 2: Cell cycle diagram 47. 
2.3. Character of the transfection host cell and media 
Host cell properties and cultivation media that are used in transient gene expression (TGE) 
systems are another important factor for efficient transfection. Screening host cell processes 
reveals that the transient productivity of secreted protein varies 10-fold among host CHO cells 
11. The transfectable cells should have the ability to grow in serum-free media at high density 5 
x106 cells/mL. In general, younger, actively dividing cells of less than 50 passages take up 
DNA better than quiescent cells 48. HEK-293 and CHO cells are the most used transfectable cell 
host in TGE systems utilizing polyethylenimine (PEI) for DNA delivery 35. Host cell 
engineering dealing with the relation between genomics/transcriptomics and protein production 
can increase the protein glycosyaltion capability of the cells. Regulating genes during 
exponential growth conditions can also increase protein productivity 49. 
Culture state characterized by working cell clone explores narrow phenotype diversity 




Hence, it is important to use a medium that supports PEI-mediated transfection. The fresh 
medium must be used if it contains chemically unstable components, such as thiamine 48. Some 
commercially available media inhibit PEI-mediated transfection due to the presence of known 
components such as dextran sulfate, heparin sulfate, ferric ammonium citrate, and certain 
hydrolysates or other unknown components 51. The presence of more salt ions in media, PEI 
amount improves the aggregation of pDNA/PEI particle size complexes and transfection 
efficiency 52. Polyplex formation was found to be sensitive to changes in the media ionic 
strength which could affect the ability of PEI to compact pDNA, protect, binding of pDNA 
extracellular and release the pDNA intracellular. Combining polyethylenimine with Fe (III) 
ions was found as a good supporting condensing agent enhances pDNA incorporation in the 
complex 53. The presence of dextran sulfate likewise iron (III) citrate components in the media 
composition can inhibit PEI transfection 54,55. 
2.4. Mechanism of polyethylenimine (PEI) mediated transient transfection 
Linear PEI consists of repeated units of aliphatic carbon groups and secondary amines 56. The 
amine group is responsible for the protonation state of the polymer, making it highly positively 
charged and condensing the pDNA to nano-polyplex size. This dual capability enables it to bind 
electrostatically with the negatively charged phosphate group of plasmid DNA as described in 
Figure 3, to compact it to nano-particle size and protect the pDNA from intracellular enzymatic 
digestion 57–59. Polyethylenimine condensation ability is based on its molecular weight. With 
branched 25 kDa PEI, the surface charge increased while polyplex size decreased compared to 
other low molecular weight PEI 60. 
 
 
Figure 3: Structure of linear PEI, pDNA nucleotide and pDNA/PEI polyplex formation. 
 




Plasmid DNA/PEI polyplex spontaneously forms in situ by addition of pDNA followed by PEI 
through electrostatic interaction. This interaction occurs between the phosphate group’s 
negative charge of pDNA nucleotide and the amine group’s positive charge of 
polyethylenimine polymer. 
Recently, it has been reported that this interaction stabilizes not only due to electrostatic 
interaction but also because of its interacting with groove atoms (minor and major grooves are 
shown in Figure 4) of the DNA nucleic acid 61. 
 
 
Figure 4: The major and minor grooves in a space-filling model of DNA 62.  
Both grooves arise from the anti-parallel arrangement of the two backbone strands. They are important in 
the attachment of the DNA-binding proteins involved in replication and transcription. 
Once the polyplex has reached the target cell, it binds to the plasma membrane proteins that are 
negatively charged, like heparin sulfate proteoglycans and integrins. The plasma membrane 
represents the first barrier which regulates the entrance of nano-particle polyplex (as illustrated 
in Figure 5). The interaction of cationic polymers with cells and nano-particle uptake have been 
reviewed 63,64. There are several mechanisms that allow small polyplexes to internalize the 
cells, including clathrin-mediated endocytosis (for endocytic vesicles with a size of ∼100–150 
nm), caveolae-mediated endocytosis (∼50–80 nm), micropinocytosis (∼90 nm) and 
macropinocytosis (∼500–2000 nm) 42,65–67. The polyplexes pass into the cells through 
endocytosis, macropinocytosis, or phagocytosis 68. Additionally, both clathrin and caveolae 
appear to be major internalization routes for PEI polyplexes 69. Generally, the polyplexes have 








Figure 5: Pinocytosis pathways and tracking pDNA/PEI polyplex 65,69. 
The protonation state of the polymer depends on pH values and salt concentration and enables 
the polyplex to escape from endo-lysosomes lysis and deliver the pDNA to the nucleus 70. 
Recent studies in atomic force microscopy (AFM) showed that sub-50-nm PEI/pDNA polyplex 
binds with nuclear pore complex without affecting the nuclear membrane 71. To date, it is still 
unknown whether the PEI dissociates from pDNA before transfection or not, and what happens 
to the PEI the fate of PEI inside the cells 72.  
2.4.1. Physico-chemical properties of pDNA/PEI polyplex 
As previously mentioned, polyplex formation occurs as a result of the ionic interaction. 
Therefore, the shape, size, stability and overall surface charge of the resulting polyplex particles 
from that interaction depends on the preparation conditions. There are two ways of pDNA/PEI 
polyplex particle preparation. The first is called the conventional method (two steps), where the 
pDNA and PEI solutions are dispersed separately in 150 mM NaCl or 278 mM glucose, then 
the PEI solution is added to the DNA and the mixture is incubated for 10 min 73 before added it 
to the cell suspension. The second is called in situ (one step), and is quite simple: the pDNA 
solution and PEI are both added to the culture without the prior preparation step 74. For both 
methods of polyplex preparation, the size and surface charge of the polyplex particle are 
important transfection parameters. The polyplex size is determined by measuring the 
hydrodynamic radius of pDNA/PEI polyplex based on dynamic light scattering (DLS) in which 
changes in the polyplex surface charge are found by measuring the zeta potential 75. Recently, 
nano-particle tracking analysis (NTA) has begun to be used to determine polyplex size, 




distribution, concentration, and for imaging 71. Also characterization of L-PEI/pDNA 
polyplexes by transmission electron microscope (TEM) is performed as described in Figure 6 
76. The PEI-pDNA nano-particles are almost spherical with a diameter of ~20‑100 nm. 
 
Figure 6: TEM image of pDNA/25kDa L‑PEI 76. 
Polyplex formation between interactions of 2 µg/14 µg, respectively. 
The particle size in pDNA/PEI formation as monitored by DLS increases and then decreases 
with the PEI/DNA (N:P) molar ratio in the 2.2-15840 ratio range. At the same time, the zeta 
potential of PEI/DNA polyplex changes from negative to positive with an increase in the 





Figure 7: Schematic image showing polyplex particle size with the ratio. 
Showing the trend towards the size of PEI/DNA polyplex being related to the PEI/DNA ratio 75. 
Simulation studies investigated the stability of polyplex, finding that it depends on the charge 
distribution and transfection facilitating by free of PEI (unbound PEI particles with pDNA) 77. 
To date, the positive charge comes from the interaction between PEI amines’ positive and the 
phosphate group’s negative nucleic acid charge; this binding is facilitated by the release of 
water from the nucleic acid to form stable polyplex 61. This interaction is reversible and allows 
PEI molecules to replace each other, as described in a previously reported simulation study 78 
One of the important properties required for a transfectable polyplex molecule is the surface 
charge, which is usually determined by measurement of the zeta potential. It is well known that 
only a high +/- charge ratio of polyethylenimine polyplexes improves transfection where free 




enhances binding to the anionic cell membrane 79. On the other hand, it was reported that free 
PEI can mediate toxicities before uptake by cells through membrane destabilization and after 
entering into the cells, thus inducing apoptosis 80. At the same time, to overcome the problem 
that high transfection efficiency is accompanied by high cytotoxicity, it may be possible to 
optimize the concentration of pDNA, PEI and host cells. 
2.5. Optimization of PEI transient transfection conditions  
In addition to choosing a high-performance host cell line and medium for cultivation, the ratio 
of pDNA:PEI plays a very important role in the transfection of mammalian cells. Screening of 
the transfection parameters, including media, cell type, and the ratio of PEI to DNA in response 
to protein expression time are crucial steps in determining the optimum conditions for 
maximizing protein expression 57,81. Dilution of transient transfection culture with 
hyperosmolar media of 490 mOsm kg-1 can increase productivity 4-fold and also reduce cell 
growth 82. Even the method of PEI/pDNA polyplex formation, either through in situ or 
conventional methods, affects gene expression. Higher transfection efficiency was obtained 
with the one-step transfection procedure with higher cell densities and higher concentrations of 
PEI and DNA. In addition, in situ polyplex formation is more amenable to up-caling and GMP 
compliance because of the lower contamination risk and easier handling involved 44,74. In situ 
transfection under hypothermic conditions increases volumetric recombinant protein yield. This 
ca. two-fold increase coincides with a reduction in the amount of both PEI and plasmid DNA 
used. This study was performed with 4 x106 cells/mL cell density and without a media dilution 
step after transfection 83. Polyplex cellular uptake is dependent on the PEI/pDNA ratio, the cell 
density at the time of transfection, and the extent of particle aggregation. The rate of particle 
uptake was constant within the first 60 min post-transfection at a DNA:PEI ratio of 1:2 (w/w) 
and at a cell density of 2 x106 cells/mL. Aggregates become larger over time 84. 
Another Design of Experiment (DoE) study explored how productivity titer increased with a 
parallel increase in cell density and PEI concentration while fixing the pDNA concentration 85. 
Normally transient transfection introduces foreign DNA without integrating it into the genome, 
but the genes are expressed for a limited time (24–96 hr), thus transient transfection is hindered 
by a short expression period and low productivity in comparison to constant gene expression. 
Repeated transient gene expression is applied to prolong the productivity time and improve 
productivity 4- to 12-fold based on harvest time 86. The repeated transient transfection approach 
is described in Figure 8. 
 





Figure 8: Flow diagram explaining the repeated transient transfection process. 
T1 to T5 stand for transfection number. 
Generally, it is quite difficult to compare all these findings due to the difference in PEI:pDNA 
ratio, mixing order, incubation time, different polyplexes concentrations, medium composition, 
volume, cultivation vessel, and cell type. All of these variables reflect the need to optimize the 
method of transfection in CHO-K1 cells.  
2.5.1. Design of Experiment (DoE) approach for transfection optimization  
Gene delivery into cells by a process of transient transfection is influenced by a number of 
interrelated factors as presented in Figure 9. Optimizing this complex process requires the study 
of these factors in isolation and in combination. The DoE method is an essential modeling tool 
for this purpose.  
A wide range of optimized PEI and DNA amounts have been reported in the literature, using a 
range of media types, cell lines, vectors. The most important factors to consider in optimizing 
transfection include the cell density, PEI and plasmid DNA concentration at the time of 
transfection. The easiest way to handle problems with multiple factors is to start by fixing one 
factor and then bring in other factors one after another, a procedure called ‘‘One Factor At a 
Time’’ (OFAT) 39 and referred to as the “independent” way. 
The DoE approach is superior to OFAT in that it more quickly investigates the interrelation 
(“dependent” way) amongst a number of factors and requires fewer experiments for all factors 
at the same time. The DoE methodology is particularly preferable when the optimal condition 







Figure 9: Interacting variables underpinning transient transfection process. 
Mammalian host cell based transient production process design 11. 
DoE screening is used at the beginning of the experimental procedure to explore how many 
factors could affect the process and to identify their appropriate ranges. This is followed by the 
optimization step, which predicts the response value for all possible combination factors within 
the experimental region and identifies the optimal experimental point. The DoE methodology 
can design a series of experiments to be conducted in parallel. This helps in monitoring the 
process which is influenced by many factors, in estimating the interaction of factors, and in 
distinguishing between the noise and real effects.  
DoE findings represented by a contour plot display the relationship between input factors and 
responses. When the objective is screening, full factorial designs can easily be run, but the 
number of experiments would increase dramatically by a number of factors. Therefore 
fractional factorial designs are used to reduce the number of experiments. This design is based 
on linear or polynomial interaction. Hence, optimization of the already identified factor is 
required, a quadratic model is flexible and closely the relationship between factors and response 
named response surface modeling (RSM). One of the commonly used RSM designs which is 
applied in this study is a central composite circumscribed (CCC) 87,88. 
2.6. Transforming growth factor-β (TGF-ß) superfamily 
After achieving the desired GFP-transfection efficiency with host cells in specific media and 
appropriate transfection reagent, it is important to evaluate that transfection system with other 
target recombinant proteins, like transforming growth factor beta 1 (TGF-β1) within this study. 
TGF-β1 is one of three closely related mammalian members of the large TGF-β superfamily 89. 
TGF-ß1, 2, 3 growth factors display a shared identity of about 64-82% 90. Most cell lines and 




tissues encode human TGF-β1 cDNA, a 390 amino acid (aa) precursor that contains a 29 aa 
signal peptide and a 361 aa pro-protein. The endopeptidase furin enzyme convert pro-protein 
precursor to mature moiety residues which consist of an N-terminal 249 aa latency-associated 
peptide (LAP) and a C-terminal 112 aa mature TGF-β1 91,92. Due to the absence of latent TGF-
beta binding proteins (LTBP) in CHO cells, the recombinant human TGF-β1 is generally 
produced as a small latent complex (SLC) as seen in Figure 10, where LAP binds to mature 
TGF-β1 through a non-covalent bond and an intramolecular disulfide bond 93,94. The SLC can 
be visualized on the SDS page, non-reducing as a dimer at 75 kDa 94,95 and the mature active 
TGF-ß1 dimer at 25 kDa. 
 
 
Figure 10: Cleavage of TGF-ß1 precursor. 
This graph shows the process of a dimeric recombinant TGF-ß1 protein production in CHO cells 96. 
The TGF-β family plays an important role in cell proliferation and embryo implantation 
through its biologically active form (monomer 12.5 kDa to ~17 kDa or dimer) 97,98. In vitro, the 
active (mature) form is liberated from the large latent TGF-β complex and small TGF-β 
complex under extreme pH, heating to high temperature, or in the presence of SDS and urea 92.  
Previously, the recombinant production of mature TGF-ß1 was achieved by stable transfection 
of CHO cells with improvement in the production concentration from 7 mg/L to 30 mg/L 94,99. 
More recently, Abdulkerim et al., was able to produce TGF-ß1 through lentiviral transduction 
of CHO cell 100.  
The maximum reported recombinant antibody titer in transient transfection platform was 160 
mg/L in CHO- K1 cells, estimated by enzyme-linked immunosorbent assay (ELISA) 101. 
TGF-ß1 is known to inhibit or stimulate cell growth as the bifunctional regulator, to regulate the 
immune system, and to enhance wound healing through deposition of extracellular matrix 102. It 
can inhibit the proliferation of most cell lines by inducing cell cycle G1 arrest 103. To regulate 




activation mechanisms (mentioned above) in order to act on its receptors (TGF-ß Rs), which in 
turn activate SMAD proteins 95. More details about the regulation of TGF-ß signaling through 
TGF-ß receptors in control of cell proliferation have been reported by many scientists 104,105 and 
are described in Figure 11.  
The activity of transforming growth factor beta (TGF-ß) can be determined by assessing the 
inhibition of the growth of lung epithelial cell lines 106. Bioassays for quantification of active 
and total transforming growth factor-ß are more sensitive than ELISA 107, and provide insight 
into the activation of latent TGF-ß1 to mature TGF-ß1.  
 
 
Figure 11: TGF-β1 signaling through the Smad-dependent pathway. 
Mature TGF-β1 is released by different mechanisms such as degradation of LAP by proteases, induction 
of conformational change in LAP by interaction with thrombospondin or by rupture of noncovalent bonds 
between LAP and TGF-β1. 2) Active TGFβ-1 binds to receptor type II (TβRII) which is constitutively 
phosphorylated and active. 3) The TGF-β1-TβRII complex recruits and activates TβRI by 
transphosphorylation of the GS domain. 4) The heterotetrameric receptor complex phosphorylates R-
SMAD at the C-terminal SSXS domain. SARA protein promotes the binding of R-SMAD with TβRI. 5) 
The phosphorylation of R-SMAD allows the interaction with Co-SMADs. 6) This complex can translocate 
to the nucleus, joining the DNA and inducing or modulating the transcription of different target genes. 7) 
I-SMAD can inhibit signaling through the blockade of the access of the receptor complex to R-SMAD by 
mechanical interaction or induce TβRI degradation by ubiquitination 108. 
 
 




2.6.1. Fusion TGF-ß1 recombinant protein 
After optimizing the transfection factors with GFP plasmid, there are two ways to transiently 
transfect the desired expression plasmid. The first way is the co-transfection of the dual plasmid 
system, one fluorescence GFP for monitoring transfection efficiency and the other for target 
protein 35. The second way is to replace the GFP plasmid with a target fused plasmid like pGag-
EGFP plasmid 86. This enhanced GFP (fluorescent) fused to the target protein (not fluorescent) 
allows the target protein to be monitored via fluorescence detection. Recombinant fusion 
proteins have become an important category of biopharmaceuticals. Fusion proteins were 
developed by genetically fusing two or more protein domains together to add multi-functional 
properties, such as protein purification and on-line monitoring 109,110. Florescent fusion tags are 
commonly used for detecting recombinant proteins during cultivation. Short chain tryptophan 
tag is comes superior for GFP tag family. It is compromise only 5-11% of its molecular size. 
Proteins of large molecular size may stress the host cell metabolism during production 111. The 
binding specificity of antibody recombinant protein is not affected by this tag, while an 
increasing amount of tryptophan residue slightly decreases the binding activity.  
Tryptophan has maximum excitation at 280 nm and maximum emission at 350 nm with a 
relatively high quantum yield and a larger Stokes shift than the other aromatic amino acids (~70 
nm). Its fluorescence signal is highly sensitive to the properties of the surrounding environment 
and neighboring amino acids 112. This system has been used to monitor on-line the production 
of antibody fragments in E.coli cultivated on a microtiter plate using an adapted BioLector fiber 
optic monitoring device 113,114.  
For protein purification directly from culture supernatant, short peptide affinity tags have 
become indispensable in protein downstream research. His-tag fused to recombinant protein 
provides a powerful application for purification, detection and assay of recombinant proteins100. 
Twin-Strep-tag® is particularly popular for providing recombinant proteins at high purity and 
functionality by using physiological conditions within a rapid one-step protocol. The affinity 
receptor for Twin-Strep-tag® is the engineered streptavidin, known as Strep-Tactin resin 
column chromatography. The presence of biotin in culturing media competes with Twin-Strep-
tag® binding and inactivates Strep-Tactin® columns. Therefore it is important when purifying 
Twin-Strep-tag® fusion proteins, that pH be adjusted to 8 and to remove biotin, blocking it 
using BioLock solution 70 U/ml (1 U blocks 1 µg biotin) 115.  
Implementation of short chain tryptophan (3 residues) tags for off-line protein monitoring by 
2D-florescence spectroscopy and Twin-Strep-tag® for protein purification technology was 
developed in this thesis. 
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3. Material and Methods 
3.1. Materials 
3.1.1. Plasmid DNA 
Two plasmids were used throughout this study, namely pEGFP-N1 plasmid (Figure 12) 
purchased from Clontech (Clontech Laboratories Inc., USA) and TGF-ß1 plasmid (Figure 15). 
The former was directed to express green fluorescence protein (GFP) intercellular for 
transfection efficiency evaluation. The other plasmid was targeted to extracellular expression of 
TGF-ß1 protein. TGF-ß1 plasmid orginated from integration of acceptor plasmid (Figure 13) 
with entry plasmid (Figure 14), which were purchased from IBA (IBA GmbH, Göttingen, 
Germany) using the Stargate protocol 116. 
 pEGFP-N1 plasmid map: 
 
 
Figure 12: Map of pEGFP-N1 plasmid encoded green fluorescence protein (GFP). 










Generation of TGF-ß1 production plasmid: 
TGF-ß1 production plasmid Figure 15 originated from integration of acceptor plasmid Figure 
13 with entry plasmid Figure 14 using Stargate protocol 116. 
 
 Acceptor plasmid: 
 
Figure 13: Map of pCSG-IBA-102 acceptor vector. 
The vector carries the BM40 signal sequence for secretion of the recombinant protein into the medium and 
the Twin-Strep-tag® for C-terminal fusion to the recombinant protein. The episomal replication is 
mediated through the Epstein Barr Virus replication origin (oriP). For selection and propagation in E.coli, 
the vector carries an ampicillin resistance. 
 Entry plasmid: 
 
Figure 14: Map of entry vector with target TGF-ß1 sequence and a fluorescent tag. 
This vector was integrated with the previously mentioned acceptor vector to produce the target expression 
plasmid. 
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Figure 15: Map of TGF-ß1 fusion protein destination expression plasmid. 
This represents the final TGF-ß1 production plasmid used in this study, which was prepared according to 
the manufacturer’s (IBA) instructions 117. The plasmid backbone contains ampicillin resistance gene 
(AmpR), cytomegalovirus (CMV) enhancer promoter and Epstein Barr Virus origin of replication (oriP). 
The TGF-ß1 sequence is genetically linked to the W2-tag accession number [Gen Bank: JN120907] with 
three tryptophan residues. The W2-tag is linked to the cleavable enterokinase site by a GS-linker. The 
TGF-ß1 segment is linked to Twin-Strep-Tag® for further purification as shown in the schematic diagram. 
The amino acid sequence consists of 39 amino acids (aa) for the fluorescent chain (W2-tag region), 112 aa 
for mature TGF-ß1 (monomer form) and 28 aa for Twin Strep-tag®.  
3.1.2. Sequencing primer 
pCSG forward 5´- GAGAACCCACTGCTTACTGGC -3´ 
pCSG reverse 5´- TAGAAGGCACAGTCGAGG -3´ 
3.1.3. Cells 
1) One Shot® TOP10 chemically competent E.coli was obtained from IBA (IBA GmbH, 
Göttingen, Germany); cells used for plasmid propagation. 
2) Chinese hamster ovary (CHO-K1) suspension cells were obtained from Bielefeld 
University, Germany; cells used for cultivation and protein expression by transient 
transfection. 




3) Adenocarcinoma human alveolar basal epithelial cells (A549-cells), ACC107, were 
purchased from Leibniz Institute DSMZ (German Collection of Microorganisms and 
Cell Cultures, Braunschweig, Germany). These adherent cells were used for a further 
TGF-ß1 bioactivity test.  
3.1.4. Media and supplements 
 For E.coli cultivation:  
1) LB-Agar consists of 5 g yeast extract, 1 g NaCl, 10 g Trypton, 15 g Agar added to 1 L 
ddH2O at pH 7.6  
2) LB consists of 5 g yeast extract, 1 g NaCl, 10 g Trypton added to 1 L ddH2O at pH 7.6 
 For CHO-K1 cell cultivation and transfection: 
Table 1: List of media and supplement. 
Media type Suppliers  
CHOMACS CD  Miltenyi Biotec, Germany 
CD CHO Thermo Fisher Scientific, Germany 
ProCHO-5 Lonza, Sartorius AG, Germany 
Ex-cell CD CHO Sigma-Aldrich, Germany 
Opti-MEM Gibco, Thermo Fisher Scientific, Germany 
DMEM/F12 Thermo Fisher Scientific, Germany 
L-Glutamine added at conc. of 8 mM/L Biochrom, Germany 
 For osmotic pressure: 
CHOMACS CD media with different osmolality was prepared by addition of NaCl directly to 
the media, and osmolality was measured with the Osmomat 3000 (Gonotec GmbH, Germany). 
 For A549-cell cultivation: 
1) DMEM media for A549-cell cultivation obtained from Life Technologies, Germany. 
2) Fetal calf serum (FCS) purchased from PAA Laboratories GmbH, Austria. 
3.1.5. Transfection reagent polyethylenimine (PEI) 
Polyethylenimine, Linear, MW 25 kDa was purchased from Polysciences GmbH, Germany. A 
stock solution of 1 mg/mL was prepared according to the Cold Spring Harbor protocol 118. 
3.1.6. Kit and accessory reagent 
1) Plasmid purification Gega Kit (Qiagen, Netherlands). 
2) Twin-Strep-tag® protein purification buffer set 10x (IBA GmbH, Göttingen, Germany). 
3) WET FRED System (IBA GmbH, Göttingen, Germany). 
4) CellTiter Blue Assay reagent purchased from (Promega GmbH, Germany). 
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3.1.7. Antibodies and commercial TGF-ß1 
Table 2: List of antibodies. 
Antibody used in ELISA and Westen blot Manufacturer, Country 
Primary antibody mouse-anti-human-TGF-β1 Dianova GmbH, Germany 
Second goat anti-mouse IgG AP-conjugate BD Biosciences Pharmingen, USA 
Second goat anti-mouse IgG HR-conjugate BD Biosciences Pharmingen, USA 
Commercial human TGF-β1 recombinant protein  Peprotech GmbH, Germany  
3.1.8. Concentration of protein sample 
Vivaspin membrane (MWCO: 10,000 kDa), Sartorius Stedim Biotech, Göttingen 
Vivaspin 2 centrifugal concentrators (MWCO: 3,000 kDa), Sartorius Stedim Biotech, Göttingen 
3.1.9.  Statistical analysis  




























3.2.1.  Plasmid production, purification, quantification, and identification 
E.coli aliquots were stored at -80 °C. For transformation, 50 μL of thawed E.coli was mixed 
with 10 μL of 0.5 µg/µL plasmid DNA (pDNA). This starting transformation mixture was 
incubated on ice for 30 min then heat-shocked for 5 min at 37 °C; afterward, the bacteria were 
cooled on ice for 2 min, taken up in pre-heated 900 μL LB medium and incubated at 37 °C for 
45 min as a heat-shock. A prepared LB agar plate with 50 µg/mL kanamycin was inoculated by 
100 μL of previously transformed bacteria suspension. In the case of TGF-ß1 plasmid, the LB 
agar plate was prepared with 100 µg/mL ampicillin. The plates were incubated overnight at 37 
°C to allow only the transformed E.coli, which contains the plasmid, to grow under antibiotic 
selection pressure. The colony of bacteria carrying a specific plasmid was isolated for further 
propagation. The same antibiotic selection marker was used in LB liquid medium to scale up 
transformed cell growth and to obtain a large amount of cells.  
After scaling up, the transformed E.coli, containing the target plasmid at a total volumetric 
scale of 10 L, came from several Erlenmeyer baffled shake flasks (propagation step). The cells 
were centrifuged at 4000 rpm for 30 min, collected as a pellet and stored at -20 °C. This 
harvested bacteria pellet was used for the next plasmid extraction step which was performed 
using a Qiagen's plasmid Giga kit. 
On the day the plasmid was purified, the transformed E.coli pellet was thawed and resuspended 
in 125 mL of P1 buffer followed by an addition of 125 mL buffer P2, mixed well and incubated 
for 5 min at room temperature. Then 125 mL pre-cooled buffer P3 was added, mixed well and 
incubated for 30 min on ice. Afterward, the supernatant of cell lysate containing the plasmid 
was separated by centrifugation twice for 30 min at 14,000 xg and 4 °C.  
For pDNA purification from previous cell lysate supernatant, the activated QIAGEN-tip10000 
with QBT buffers was loaded by the cell lysate supernatant which carries the target plasmid. 
The solutions pass by gravity flow through the column. The column was washed with 600 mL 
QC buffer. pDNA was eluted with 100 mL of 65 °C pre-warmed QF buffer. The pDNA was 
precipitated by adding 70 mL of isopropanol at room temperature followed by centrifugation 
for 30 min at 14,000 xg and at 4 °C. The pellet was washed with 10 mL of 70% ethanol and 
transferred to a new 1.5 mL Eppendorf tube with ethanol for centrifugation, again at 12,000 xg 
for 10 min. The ethanol was discarded and the pDNA left to dry under a laminar flow for 15 
min then dissolved in water for further quantification with the Nanodrop ND-1000 
spectrophotometer (Thermo Fisher Scientific, Germany). All these steps were done according 
to the QIAGEN ® plasmid purification manual 119 . After the pDNA concentration was 
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determined, the plasmid and target gene were identified by agarose gel electrophoresis, which 
separates DNA fragments by size. The pDNA fragments were generated by restriction enzymes.  
Procedure: 1.5% agarose gel is used. For this purpose, 1.5 g of agarose is dissolved in 100 mL 
of 1x TAE buffer (preparation was described in Appendix section page 85) and then heated in 
the microwave for 120 s (900 watt). Subsequently, 5 μL of a Roti®Safe GelStainer is added and 
the solution is poured into a gel chamber. Stencils are then used for the sample pockets. After 
the gel has been fixed, the gel is placed in the electrophoresis chamber and superimposed with 
1x TAE buffer. A comb was withdrawn and 20 μL of the DNA samples with restriction 
enzymes (prepared according to instructions of Thermo scientific, Germany) were pipetted into 
the pockets, together with 6 μL of the 10000 bp marker (3 μL marker + 3 μL of 10x FastDigest 
Green buffer, Thermo scientific, Germany). The samples were separated at a voltage of 100 V 
for 45 min. The gels were photographed under UV excitation. 
Before getting into the mammalian cell transfection, it is important to validate the plasmid 
components. There should be a gene of interest included. The validation is achieved either by 
pDNA gel electrophoresis or sequencing and protein expression. On the one hand, the GFP 
validation was done by gel electrophoresis and expression as shown in Figure 16. On the other 
hand, TGF-β1 plasmid validation performed by gel electrophoresis, sequencing as shown in 
Figure 16 & 18 and its expression afterward in Chapter 4.4. 
 
Figure 16: Agarose gel in the target gene identification. 
A) EGFP gene with approximately 761 base pairs (bp). B) TGF-ß1 gene fused by BM40 + Tryptophane 
Tag + Twin-Strep-tag®. M: Marker. 
As shown in Figure 16A, the pEGFP-N1 plasmid was treated with the restriction enzymes Sal1 
and Not1 and the cutting was successfully performed. The EGFP gene fragment corresponded 
to the expected size of 761 bp according to the plasmid design. The delivery of the EGFP gene 
to the CHO-K1 cell was analyzed through its fluorescent protein expression. The transfection 
efficiency was always monitored in this study through measurements of the GFP+ cells 




percentage which are transfected by pEGFP-N1 plasmid at different hour’s post-transfection 
(hpt). This analysis measurement was done quantitatively with flow cytometry and qualitatively 
by observing fluorescence under a fluorescence microscope as shown in Figure 17. 
 
Figure 17: EGFP level determination by flow cytometry and a fluorescence microscope. 
Panel (A) shows comparison histograms of GFP-transfected cells and non-transfected cells (red line). The 
data was obtained with flow cytometer EPICS XL-MCL, Beckmann-Counter, USA. Panel (B) shows a 
photograph of GFP transfected sample obtained with a fluorescence contrast microscope. The image was 
obtained from submitted work using media combination Opti-MEM + CHOMACS CD 50:50 (v/v). This 
protocol was not used here in this study. 
 Flow cytometric analysis:  
For flow cytometric analysis, one million cells are collected from pEGFP-N1 transfected 
culture and from non-transfected culture then centrifuged for 5 min at 200 g and resuspended in 
1 mL of 1x PBS. The sample is then analyzed on the flow cytometer BD Accuri™ C6. 
Generally, the data obtained show different histograms and dot plots produced from FL1-H of 
non-transfected samples and transfected ones, which represents the transfection efficiency 
percent as shown in Figure 34. 
 Microscopical analysis:  
Cells were photographed by fluorescence microscope (Olympus 1X 50) equipped with a digital 
camera and an image analysis system with an N.B filter. 
Also, validation of TGf-ß1 plasmid design encoding mature TGF-ß1 protein tagged with 
tryptophan and Twin-Strep-tag® was performed either by digesting the plasmid with Xba1 and 
Hind III restriction enzymes. The expected size of the DNA fragment was 667 bp according to 
the plasmid design. Gel electrophoresis analysis shown in Figure 16B confirms that the 
produced DNA fragment of digestion was this size. Furthermore, to confirm that the fragment 
had a TGF-ß1 gene sequence with fusion tags of about 453 bp according to the plasmid design 
in Figure 15, DNA sequencing results in Figure 18 show that TGF-β1 was successfully 
integrated into the acceptor vector and was 100% identical to the TGF-β1 sequence. 
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 DNA sequencing analysis:  
For the sequencing of the pDNA, 15 μL of the purified plasmid DNA solution to be examined 
were sent to the company EurofinsGenomics with 5 μL of the primer. The solution has a pDNA 
concentration of 70 ng/μL. The results of the sequencing were evaluated with the CLC 
Sequence Viewer as shown in Figure 18. 
 
Figure 18: Alignment of pDNA sequences with the TGF-β1 gene. 
The forward and reverse primer sequence was used to sequence target plasmid. Listed is the TGF-β1 
sequence (453 bp) from whole TGF-β1 expression plasmid 10767 bp. 




3.2.2. CHO-K1 transient transfection and further analysis 
For routine cell cultivation, the CHO cell suspension is grown in shake flasks at 150 rpm of 20 
mm orbital shaker and in Tubespin bioreactor®50 at 270 rpm of 10 mm orbital shaker as shown 
in Appendix section Figure 44. The cultures were kept at 37 °C., 5% CO2 and 95% humidity in 
the incubator and continuously shaken.  
The culture was taken twice a week in fresh CHOMACS CD medium to obtain highly active 
cell growth with a viability of 99%. Automated counting of the cells and cell viability using the 
Trypan blue exclusion method were performed with the Cedex analyzer (Cedex Roche 
Innovates, Germany). The cell suspension was centrifuged at 200 xg for 5 min and the 
supernatant discarded. The cell pellet was resuspended in as much fresh medium necessary to 
reach an optimal cell density of 0.5 x106 cells/mL.  
Cultivation in the Tubespin bioreactor®50 was found to be a good alternative to shake flasks. It 
has the advantage of needing only a small culture cultivation volume of 1 mL. Furthermore, this 
kind of cultivation vessel is suitable to obtain higher cell densities of up to 16 x106 cells/ml and 
for high throughput cell cultivation 120,121.  
Pre-culture is the last culture prepared before transfection. Usually, the pre-culture is prepared 
one day before transfection. Cells with a viability of more than 99% were obtained from the 
routine cultivation shake flask or Tubespin bioreactor®50 to inoculate new fresh medium at a 
cell density of 1.3-1.5 x106 cells/mL.  
For media screening, the transfection was carried out according to procedure (A) or (B) as 
following: 
 Procedure A (transfection without dilution): 
Media volume of 5 mL was treated with 10 million cells (pre-culture viability > 99%) 
and kept in the incubator for 1 hr to obtain single dispersed cells in solution and to 
guarantee homogenous cell dispersion. At transfection time, 6 µg or 8 µg pDNA (3.6 
µg/µL stock solution), and 30 µg PEI (1 mg/mL) were added. Here transfection culture 
volume and final culture volume are the same. The experiments were done once for each 
condition. 
 Procedure B (transfection with dilution):  
Based on procedure (A), procedure (B) was developed by modifying transfection media 
volume to 1 mL, which was treated at transfection time with the same amount of cells, 
pDNA, and PEI as for procedure (A). After 5 hours post-transfection (hpt), the final 
volumes of all transfected cultures were adjusted to 5 mL (equivalent to procedure A). 
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Here the screening transfection procedure was carried out in a reduced culture volume 










Figure 19: Describing media screening for transfection in two stages Procedures (A & B). 
Both procedure (A & B) were transfected with the same amount of cells, pDNA, and PEI but in media 
volume 5 mL or 1 mL respectively.  
Further transient transfection protocols were conducted in this study based on procedure (B) as 
summarized in Table 3.  
To standardize the experimental setup, all the following transfection protocols were performed 
unless otherwise stated in the Tubespin bioreactor®50 at 1 mL transfection culture volume. Pre-
culture cells 24 hrs of age was resusepnded in fresh CHOMACS CD medium. Cells were 
dispersed through shaking in a CO2 incubator for 1 hour. This was followed by the addition of 
pDNA and polyethylenimine linear PEI 25 kDa transfection reagent simultaneously with the 
cell culture, known as the in situ transient transfection process. After 5 hpt the transfection 
culture was diluted by an equal volume of fresh media. All cultures were harvested at 48 hpt for 













 Both final transfected culture volumes are similar  




Table 3: Summary of transfection protocol conditions. 
transf. =transfection, Tubespin. =Tubespin bioreactor®50 and shake fla= shake flask 
 Design of Experiments (DoE): 
Several experiments were conducted based on the design of experiment (DoE) approach to 
obtain optimal results. The experiments were done firstly by full factorial analysis design: three 
factors involving cell density, pDNA amount, and PEI amount in two levels from the central 
point. The central point was repeated four times to validate the model design shown in Table 8. 
This was followed by a series of experiments under fixed cell density conditions using central 
composite circumscribed (CCC) designs with the two factors, PEI and pDNA, in two level 
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MODDE software program (modde 9 umetrics, Sweden). The list of factors and variation 
ranges are shown in the Appendices section, pages 89-91.  
 Cell cycle analysis: 
One million cells were collected from each pre-culture age, ranging from 0 hr to 120 hr before 
transfection, then centrifuged for 5 min at 200 xg and resuspended in 1 mL of 1x PBS. The cells 
were fixed by taking up a cell pellet in 300 μL of PBS and diluting this slowly by directly 
adding 700 μL of 100% ethanol drop by drop. The solution was left on ice for at least 1 hour 
before storing it at -20 °C.  
On the day of analysis, the previously fixed cells were collected again in pellets and 
resuspended in 425 μL of PBS buffer treated with 50 μL of RNAse solution (1 mg/mL, DNAse 
free) to ensure only DNA rather than RNA would be stained. This was followed by incubation 
for 20 min at 37 °C in a water bath. Before measuring with flow cytometer at fluorescence 
(FL3) channel, 25 μL of propidium iodide stain solution (1 mg/mL) was added to distinguish 
the cell population according to the changes in cellular DNA content.  
 Polyplex characterization analysis: 
Nano-particle tracking analysis (NTA, Malvern Instruments Ltd.) allows sizing, counting and 
visualizing of the pDNA/PEI particle polyplex formation between the electrostatic interaction 
of oppositely charged pDNA and PEI. The exact number of particles per mL is measured by 
nano-tracking analysis. The device is equipped with a sample chamber and a 405 nm blue laser. 
All measurements were made at room temperature and within a tracking time of 80 minutes 
(min). An EMCCD camera and NTA software were used for size measurement. Freshly 
prepared polyplexes at a concentration of 24 µg pDNA:24µg PEI and 24µg pDNA:45µg PEI 
per 1 mL CHOMACS CD medium were analyzed. The analysis was done under static (non- 
shaking) condition. 
As described above, 5 kV analyses were carried out using the scanning electron microscope 
(SEM) (phenom desktop scanning electron microscope G1) with a backscatter electron detector 
thermionic source. A droplet from each sample was deposited on clean coverslips and kept 
overnight at 4 °C to allow the material to attach to the glass coverslips. The coverslips were 
carefully rinsed several times with distilled H2O then dehydrated through immersion in ethanol 
and dried in the oven at 60 °C for 6 hrs. After sputter coating, the samples were examined under 
microscope. 
 




3.2.3. Transforming growth factor (TGF-ß1) protein analytics 
Fused recombinant protein was purified with short peptide affinity tags such as the Twin-Strep-
tag® directly from the culture supernatant using Strep-Tactin® affinity resins. For efficient 
purification of Strep-tag-fused recombinant protein, the pH has to be adjusted to 8. However, 
some culture media supplemented with biotin competes with the Twin-Strep-tag® binding site 
and inactivates Strep-Tactin® columns. Seven mL/L of the BioLock® solution was used to 
complete the biotin blocking task 115.  
For purification, all supernatants of TGF-β1 transfected cultures were centrifuged for 30 min at 
4000 rpm at 4 °C and the pellets were discarded. The pH of the supernatant was adjusted to pH 
8.0 with 1x wash buffer (W1): 1 M Tris-Cl, 1.5 M NaCl, 10 mM EDTA at pH 10. At the same 
time, the column was equilibrated with 1X W1 buffer at pH 8.0 while being cooled. The 
supernatant was loaded onto the column using the WetFred System (Figure 20). The column 
was washed with 1x W1 buffer 5 times then once with elution buffer (E): 1 M Tris-Cl, 1.5 M 
NaCl, 10 mM EDTA, 25 mM desthiobiotin at pH 8.0 was added three times to extract the target 
protein in fractions E1, E2 and E3. To reuse the column, regenerated buffer was loaded 




Figure 20: Structure of the WetFred purification system 
This system was used for Twin-Strep-tag® protein purification. 
The concentration of purified protein was determined based on the spectrum measurement of 
Nanodrop ND-1000 UV-Vis Spectrophotometer at 280 nm. After that several samples were 
used to perform Western blots. 
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 Protein quantification by ELISA 
10 μL of protein extracted in elution buffer was taken up in 90 μL Na2CO3/NaHCO3 buffer and 
incubated in 96-well polystyrene plates overnight at 4 °C. Thereafter, the protein sample was 
stacked with the plate. On the next day, the plate was washed three times with 200 µL of 1x 
TBS buffer 1 L: 50 mM Tris-Cl, 150 mM NaCl at pH 7.6. The plate was then blocked with 200 
µL of TBS (5% skimmed milk) at room temperature for 2 hrs and afterwards washed three 
times with TBS buffer. All samples on the plate were then incubated with 100 µL of the 
primary antibody mouse-anti-human-TGF-β1 solution at a final concentration of 8 μg/mL of 
diluent solution for 1 hr at room temperature. After this, the samples were washed three times 
with 200 µL of 1x TBS buffer and then incubated for 1 hr at room temperature with 100 µL of 
the second antibody goat Anti-Mouse IgG HR-conjugate solution at a final concentration of 4 
μg/mL of diluent solution. Subsequently, it was washed again three times with 1x TBS. Of 
course with each washing step, the solution was discarded completely by inverting the plate 
several times onto tissue paper. 
The color development was started by adding the staining solutions peroxidase substrate 
tetramethylbenzidine (TMB) 100 µL to each well. The reaction was stopped after 30 min with 
the addition of 100 μL 1 M H2SO4, and the color changed from blue to yellow. The O.D. was 
detected using a 96-well plate reader Multiskan™ GO Microplate Spectrophotometer (Thermo 
Scientific, Germany) at 450 nm absorbance. The concentration of purified active TGF-ß1 in the 
elution was calculated by correlating each sample to the standard calibration curve of 
commercial TGF-ß1 presented in Appendix (Figure 47). 
 Protein qualification by SDS-PAGE and Western blot 
SDS-PAGE was applied for separating protein bands to detect a specific TGF-ß1 protein band. 
After SDS-PAGE and electro-transfer of the protein to a membrane, the Western blot protocol 
was applied.  
A polyacrylamide gel is formed by crosslinking acrylamide with N, N-methylene 
bisacrylamide. Ammonium persulfate (APS) is an oxidizing agent used with 
tetramethylethylenediamine (TEMED) to catalyze the polymerization of acrylamide and 
bisacrylamide to prepare polyacrylamide gels for electrophoresis. 
Procedure: The 15% separating gel is poured between two glass plates. After the 
polymerization, the 6% stacking gel is poured over the separating gel. This is left standing with 
a comb until it is solid. The protein samples are mixed in equal portions with Laemmli buffer: 
800 µl of 2x SDS buffer (20 mg of bromophenol blue, 58 mg of EDTA sodium salt, 5 g of SDS, 
0.315 g of tris-HCl, and 80 mL of ddH2O), 100µl glycerin at 55%, 100µl ß-mercaptoethanol, 




and shaken for 10 min at 95 °C. The electrophoresis chamber is then filled with 1x SDS 
running buffer: 0.3 g tris, 14.0 g glycine, and 1.0 g SDS are added to 1 L ddH2O at pH 8.3 and 
the polymerized gel is placed in the chamber. The comb is carefully removed from the gel. In 
the case of gels with ten pockets, 17 μL of the prepared samples are applied to the gel bags as 
well as to a gel bag with 4 μL of the molecular weight marker. The electrophoretic separation is 
carried out for about 2 hrs at a voltage of 100 V until the running front (bromophenol blue) 
reaches the end of the gel. 
By means of the Western blot, the protein band from the SDS-page gels is transferred to the 
PVDF membranes; the target protein band can then be detected using specific antibodies. 
Procedure: First, the PVDF membranes are stored in methanol for 20 min. The membrane is 
then transferred to the transfer buffer and incubated for at least 5 min. A Whatman-paper 
immersed in transfer buffer is then placed onto the anode of the blotting apparatus. Now the 
PVDF membrane and SDS-PAGE gel are placed over it. This is followed by another wet 
Whatman-paper. The blots are moistened with transfer buffer: 0.3 g tris, 1.5 g glycine, 20 mL 
methanol, and 0.1% SDS and the apparatus is sealed. The blotting is carried out for 45 min at 
15 V. The membrane is then swirled briefly in ddH2O. To saturate free binding sites, the 
membrane is incubated overnight in the block solution: 5 g of skimmed milk powder, 500 μL of 
Tween 20, to 100 mL of 1x PBS at 4 °C. The membrane is then washed three times for 5 min in 
PBST (500 mL PBS buffer + 0.5% Tween 20) 1x PBS buffer: 8 g NaCl, 0.2 g KCl, 1.44 g 
Na2HPO4, 0.27 g KH2PO4, add 100 mL ddH2O at pH 7. This is followed by membrane 
incubation for one hour in 20 mL of the primary antibody solution (3 µg/mL of diluent solution 
as shown in Appendix). The membrane is then washed three times again with PBST for 5 min. 
This is followed by its incubation for one hour in the secondary antibody solution (0.2 µg/mL 
of diluent solution). Again, the membrane is washed 3 times for 5 min with PBST and once for 
10 min in alkaline phosphatase buffer (AP buffer: 100 mM tris HCl, 100 mM NaCl, 5 mM 
MgCl2 7H2O, added to 25 mL ddH2O at pH 9.5). The membrane is developed with 25 mL of 
the AP staining solution: 250 μL color reagent A, 250 μL color reagent B, added to 25 mL AP 
buffer. The staining is stopped by transferring the membrane to ddH2O. 
 2D-Fluorescence spectroscopy 
Two-dimensional fluorescence (2D-fluorescence spectroscopy, Hitachi model F 7000, Japan) 
intensity scans analyzed the fluorescence intensity of 1 mL purified TGF-ß1 in the elution 
buffer E2 fraction with different concentrations as estimated with the nanodrop method. 
Fluorescence spectra were measured using a fluorescence spectrophotometer with horizontal 
beam geometry in a standard cuvette. The parameters had an excitation wavelength of 200–550 
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nm and an emission wavelength of 250–550 nm (20 nm steps). The whole spectrum was 
obtained within 400 V (scan speed: 2400 nm/min). 
3.2.4. Protein bioactivity determination (cell-based assay) 
 A549 cell cultivation 
A549 cells were maintained in DMEM supplemented with 10% fetal calf serum (FCS) and 1% 
penicillin/streptomycin and subcultured until required for assay treatment. Cultures were 
incubated at 37 ± 1 °C in a humidified atmosphere of 5 ± 1% (v/v) CO2 in air. The cell number 
in the trypsinized cell suspension was determined using a haemocytometer.  
The cells were washed with warm PBS buffer and then incubated with a Trypsin/EDTA 
buffered solution at 37 °C for 5 min in an incubator. After that, the equivalent amount of serum-
enriched medium was added to stop trypsinization and to prevent cell damage. Detached cells 
were collected and washed twice with PBS through centrifugation at 300 xg for 5 min. The 
supernatant was discarded and the harvested cells were counted and seeded in 96-well plates in 
fresh DMEM media with 10% FCS. The cell suspension was diluted to give a final 
concentration of 4x104 cell/ml, and 200 µl was pipetted into each well of the 96-well plate (i.e. 
8000 cells/well). After a 24h adhesion time, the incubation medium was removed and DMEM 
supplemented with 1% FCS and various TGF-ß1 concentrations ranging from 44 ng/mL to 176 
ng/ml and controls (0 ng/ml) were added. Each concentration was tested in four independent 
wells. The inoculated plates were incubated in a CO2-incubator at 37 °C, 5% (v/v) CO2 and at 
90% relative humidity for five days. 
 CellTiter-Blue Assay 
After visual assessment, the TGF-ß1-containing media and negative controls were removed and 
an indirect estimation of cell proliferation was made using a CellTiter-Blue® Cell Viability 
Assay (Promega, Cat. Number G8080). A working solution of CellTiter-Blue reagent in 
DMEM or alpha-MEM without antibiotics and serum was prepared: 1 mL CellTiter-Blue 
reagent + 9 mL DMEM (10 mL of total volume). After the medium was removed, 100 µL of 
the working solution was added to each well with the help of a repeating pipette. Additionally, 
4 side wells without cells were filled with CellTiter Blue working solution for the blank 
measurement. The plates were incubated at 37 ± 1 °C in a humidified atmosphere of 5 ± 1% 
(v/v) CO2 in air for approximately 4 hours. The fluorescence was determined at 560 nm 
(excitation) and 590 nm (emission). The dye used for this assay is the blue, non-fluorescent 
resazurin (7-hydroxy-3h-phenoxazin-3-one-10-oxide). In the mitochondria of living cells, it is 
reduced to the pink fluorescent resorufin. Thus a measure of the metabolic activity of the living 






Production of recombinant proteins is important for therapeutic and research development 
purposes. Establishing efficient transient protein expression is a prerequisite for the rapid 
delivery and production of these recombinant proteins.  
Methods of transient transfection depend on a number of different factors, including media 
type, cell density, physiological state and age of the culture, and the amount of plasmid and 
transfection reagent. Therefore, it is necessary to develop a reproducible transfection protocol to 
rapidly produce proteins of adequate quality and quantity. For this reason, the goal of this thesis 
has been to develop a novel means of cost-efficient transfection by optimizing the parameters of 
the transfection process that have an impact on transfection efficiency and cell viability. To do 
so we used linear polyethylenimine (PEI) polymer as a transfection reagent and green 
fluorescence protein (GFP) expression plasmid as a model for protein expression.  
After optimizing the transfection process, we applied the method for producing transforming 
growth factor TGF-ß1 protein, which was then purified. The next step was detection by 
Western blot and 2D-fluorescence spectroscopy. In the same time, the concentration was 
determined with a Nanodrop spectrophotometer and ELISA methods. Finally, the bioactivity 
was tested through a cell growth inhibition assay. 
The major objectives of this work are divided into four chapters. The first chapter focusses on 
establishing a suitable transient transfection procedure in CHOMACS CD serum-free media. 
This helps in the development of an efficient routine transfection protocol that combines high 
transfection efficiency with high cell viability. The next chapter takes into account a wide range 
of variables relating to the cell culture in the routine transfection protocol. These variables 
include pre-culture cell density, cell density at the time of transfection , and pre-culture age in 
relation to the cell cycle. The third chapter focusses on a wide range of pDNA and PEI amounts 
in the routine transfection protocol. Various transfection conditions were tested using the design 
of experiment (DoE) method to understand the interaction between these variables and 
transfection efficiency. Repeated transient transfection was implemented to further improve 
transfection efficiency by 60%; this extended protein expression and reduced the amount of PEI 
and pDNA per transfection step. The scalability of the routine transfection protocol from 1 mL 
to 12.5 mL was evaluated using the Tubespin bioreactor®50 and shake flasks. The last chapter 
focuses on the transient expression of recombinant transforming growth factor TGF-ß1 protein 
in shake flasks. This chapter provides preliminary information about using 2D-fluorescence 
spectroscopy to detect purified TGF-ß1 protein regarding their concentrations. Finally, the 




4.1. Transient transfection in CHOMACS CD media 
Cell culture media represent the first barrier that faces the PEI/pDNA transfection polyplex 
before it interacts with cells. Six different commercially available media were screened for their 
influence on cell growth (indirectly indicated by cell viability) and transfection efficiency. The 
screening was done under fixed transfection parameters concerning the number of cells, i.e. the 
amount of pDNA and PEI, but involving two different volumes of transfection culture. The first 
of these is the large culture volume (5 mL) called here “procedure (A)”. The second is the small 
culture volume (1 mL) called here “procedure (B)”. In an indirect way procedure (A) exerts the 
transfection parameters in a lower concentration than procedure (B), as described in ‘Materials 
and Methods’ section Figure 19. Furthermore, this study used procedure (B) to evaluate the 
effect of adding media at different post-transfection time points, from 1 hpt up to 20 hpt. We 
extended the study to also investigate the necessity of adding media at 5 hpt, which coincides 
with the up-scaling of the transfected culture volume. The need to exchange the medium prior 
























4.1.1. Screening of transfection medium for CHO-K1 cells 
Six different media named (ProCHO-5, CD CHO, CHOMACS CD, Ex-cell CD CHO, Opti-
MEM and DMEM/F12) were tested for transfection as shown in Figure 21. 
 
 
Figure 21: Media screen for transfection and cultivation Procedure (A).  
Screening of the transfection media was done according to the procedure (A). Transfection efficiency and 
cell viability in different transfection media (ProCHO-5, CD CHO, CHOMACS CD, Ex-Cell CD CHO, 
Opti-MEM and DMEM/F12) were determined at 24, 48, and 72 hours post-transfection (hpt). 
Cell growth and transfection efficiency are the main targets of establishing a transient  
transfection protocol. Importantly, high cell growth is indicated indirectly here by high 
viability, and high transfection is related to high transfection efficiency (TE). The media 
screening procedure (A) (Figure 21) reveals the different effects of various media on cell 
growth and transfection efficiency, the two targets of the protocol. ProCHO-5 and CD CHO 
media help support both cell growth and transfection, while Opti-MEM media enhances only 
transfection. CHOMACS CD showed better results only with regard to cell growth, and 
DMEM/F12 slightly assisted transfection, unlike Ex-Cell CD CHO.  
This result clearly shows that ProCHO-5 and CD CHO media are the best choices for achieving 
the targets of supporting transfection and growth and that the other media are not suitable for 
this purpose. However, the media which support either transfection or growth can also be made 
to support both targets (transfection and growth), and hence were tested by using the alternative 
method of transfection and adapting CHO cells to grow in such media. For this reason, rather 
than neglecting CHOMACS CD the second part of this experiment was conducted with this 

















































Media screen for transfection procedure  (A) at different pDNA amount 6-8 µg
TE-24hpt [%] TE-48hpt [%] TE-72hpt [%]




As expected, the component “media” is an important factor for compatibility with PEI 
transfection, acting as either an inhibitor or supporter of the process. The transfection condition 
was modified in procedure (B) as shown in Figure 22. The idea behind this is to produce a high 
density of cells with a smaller amount of inhibitor. Transfection in Procedure (B) was carried 
out with only three media (ProCHO-5, CD CHO, and CHOMACS CD), based on the 
preliminary results (Figure 21) which showed they had the best viability record.  
 
Figure 22: Media screen for transfection according to Procedure (B). 
Transfection efficiency and cell viability were determined in the three different media of CHOMACS CD, 
ProCHO-5 and CD CHO using transfection Procedure (B). All experiments were done in duplicate. 
Transfection in low amounts of media under Procedure (B) affected the transfection efficiency 
differently, depending on the type of media (Figure 22). Transfection efficiency with 
CHOMACS CD media increased >35 fold compared to Procedure (A). Since an equal cell 
amount at high cell density was used in 1 mL CHOMACS CD (Figure 22), this increases the 
cell polyplex (CHO/PEI/pDNA) interaction. Thus the (CHO/PEI/pDNA) interaction was better 
in low media volume (1 mL) but not the best with high media volume (Figure 21). The better 
efficiency can be explained by the presence of a number of media components that interacted 
negatively with the pDNA/PEI polyplex. This interaction could occur through blocking or 
neutralizing the charge of pDNA/PEI polyplex. Accordingly, with regard to the pDNA/PEI 
polyplex aspect, the presence of such negative components in CHOMACS CD is greater in the 
5-mL-volume with Procedure (A) than in the 1-mL-volume with Procedure (B). Therefore the 



















































Media screen for transfection Procedure (B) with different amounts of pDNA
TE-24hpt [%] TE-48hpt [%] TE-72hpt [%] Viability-5hpt [%]





The highest transfection efficiency was achieved with 5 mL ProCHO-5 in Procedure (A), where 
high media volume was used for a transfection of nearly 70% at 72 hpt (Figure 21), but with a 
culture volume of 1 mL and Procedure (B) the transfection efficiency of the same media was 
decreased to 35%. Interestingly, the CD CHO media showed the same tendency, with around 
60% in the 5-mL volume and 30% in the 1-mL volume.  
This transfection behavior is contrary to that of the CHOMACS CD media, where the influence 
of inhibited media components on PEI-mediated transfection was clear. This influence had a 
less negative impact in the 5-mL transfection volume for both ProCHO-5 and CD CHO 
compared to CHOMACS CD. Apparently, the different methods of transfection in the two 
procedures (A & B) can determine whether the media supports high cell density transfection or 
low density transfection. The high cell density transfection with Procedure (B) was used as a 
starting point towards improving transfection efficiency in the CHOMACS CD media used in 
this study. To explore the robustness and flexibility of Procedure (B) for transfection, we 
studied the effect on transfection efficiency of extending or shortening the post-transfection 
time of 5 hpt before the stage of transfected culture dilution. 
4.1.2. Determination of post-transfection time required before media dilution 
With the aim of determining whether increasing or decreasing the post-transfection time could 
affect transfection efficiency, different numbers of hours post-transfection (hpt) , i.e. 1, 5, 10 
and 20 hpt were evaluated. According to the hypothesis that the media has an inhibitory effect 
(comes from media dilution) on pDNA/PEI polyplex mediated transfection, the expectation 
would be that dilution occurring after only a few hours post-transfection (hpt) would have a 
more negative impact on transfection than dilution at a later hpt. This is because the effect is 
greater after subsequent additions of media 1:1 (v/v), which interact with the polyplex and exert 
an inhibitory effect.  
CHO-K1 cells were transfected on an initial volume of 1 mL with the addition of one volume of 
media (media volume addition was reduced from 4 to 1 mL), modified from the previously 
mentioned Procedure (B). From now and hereafter (unless otherwise stated) pDNA and PEI 
amounts were modified to 24 µg pDNA and 45 µg PEI rather than 6, 8 µg for pDNA and 30 µg 
for the PEI as described in the previous experiments. This change was based on DoE studies 
described in Chapter 4.3 to obtain high transfection efficiency.  
Interestingly, the findings confirm previous expectations concerning the ability of media 
components to inhibit PEI transfection. The transfection efficiency was lower in cultures 
transfected for 1 hpt, while other cultures transfected in the 5-20 hpt range have a similarly 




with 1 hpt, showed relatively higher cell viability compared to those with 5, 10, 20 hpt. This 
reflects the inverse relationship trend between transfection efficiency and viability percentage. 
 
 
Figure 23: Effect of post-transfection time prior to dilution. 
CHO-K1 cells transfected in a constant culture volume of 1 mL as in Procedure (B) followed by an equal 
volume addition of media. The additions were made at the indicated hours post-transfection (hpt). The 
cultures were harvested to determine transfection efficiency and measure viability at only 48 hpt to avoid 
further starvation stress.  
The data in Figure 23 shows that extending post-transfection times from 5 to 20 hours before 
transfected culture dilution provides no further increase in transfection efficiency, and also that 
reducing this time to 1 hpt resulted in relatively low transfection efficiency. The expectation 
was that increasing transfection time would allow such delayed cells that were not in mitotic 
stage (cell cycle) to enter it and maintain the pDNA/PEI polyplex. Unfortunately, no 
improvement in transfection efficiency occurred. This could be due to two limitations. First, the 
PEI/pDNA polyplex aggregate over time and become bigger in size, which means they cannot 
pass through the cell membrane via pinocytosis. Second, the cells were saturated by the amount 
of PEI/pDNA polyplex which had already passed through by the 5 hpt period.  
These results indicate that 5 hpt is enough time to allow the entrance of transfection polyplex 
and that a further increase in transfection time before culture dilution has no effect on 
transfection efficiency and viability. To confirm this finding, the transfected culture was diluted 
with a different volume of media as described in the experiment below. Generally, this result 
also indicates that during scale-up transient transfection, there is no need to dilute the culture at 
a fixed time after 5 hpt. Of course, this flexibility in media addition time, gives us more chance 
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4.1.3. Effect of additions to media volume on transfected culture at 5 hpt 
As discussed above, the pDNA/PEI polyplex has enough time to enter the cells within 5 hpt. 
Now the study evaluate the necessity of adding one volume of medium at the 5-hpt time point, 
and test the effect of volumetric scale-up (addition of 1-7 volumes of culture media) on 
transfection efficiency (further confirmation for the previously mentioned media component 
inhibitory hypothesis). The expectation was that additions of different volumes of media at the 
5-hpt time point should not have a negative impact on transfection efficiency. Cultures of CHO-
K1 cells were resuspended and transfected with an initial volume of 1 mL according to 
Procedure (B) in a Tubespin bioreactor®50 with four different dilution volumes at 5 hpt: (1) no 
media addition, (2) addition of one volume (1 mL) of media, (3) addition of 3 volumes (3 mL) 
of media and (4) addition of 7 volumes (7 mL) of media.  
 
 
Figure 24: Different volumes of media added at 5 hpt. 
Effect of media additions after transfection 5 hours post-transfection time (hpt) on transfection efficiency 
and cell viability% were described. All experiments were done in triplicate. 
The results in Figure 24 demonstrates that as expected transfection efficiency was about similar 
for all four tested conditions, and that it is not necessary to dilute the culture after transfection. 
In addition, transfection efficiency remained stable in all cultures, regardless of media addition 
at 5 hpt in the tested ranges of 1:1 to 1:7 (v/v). The data confirm the feasibility of volumetric 
scale-up for the transfected culture by the strategy of adding media. This will increase the 
period of recombinant protein expression. Overall, the transfection efficiency obtained was 
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Generally, transfection efficiency level was high at 48 hpt and increased by increasing post-
transfection time to 72 hpt, but further increasing it decreased to the same level of 48 hpt. This 
behavior may be explained by the increasing growth of a non-transfected cell (GFP-cell) 
population compared to a transfected one (GFP+ cell) within the same culture during the time 
period 72 to 96 hpt. Another explanation is that this is due to the loss of plasmid DNA (pDNA) 
through extended cultivation time because it’s episomal and there is loss by cell division. 
According to this experiment, 72 hpt represents the maximum point of reporter GFP expression 
and 48 hpt is an optimal point for harvesting the culture. However, viability remained higher 
above 95% in all transfected cultures, which is a good indicator for cell growth activity. In 
order to avoid deterioration of viability in the cultures with no media addition or with a low 
volume of added media, the culture harvested earlier. 
It is worth comparing the efficiency of transfection within the individual experiments carried 
out. The efficiency of transfection with a low amount of pDNA 6 µg combined with 30 µg PEI 
ranged from 52% (Figure 24) to 38% (Figure 22). This variability in the percent values of 
transfection efficiency could be related to the physiological intra-variability of the cultures or 
the stability of the formed pDNA/PEI polyplex. This observation endorses the use of a high 
amount of 24 µg pDNA:45 µg PEI (mentioned previously) as a routine transfection protocol. 
This is recommended for repeated assessment within and between the conducted experiments. 
Perhaps the high amount of pDNA and PEI forming stable polyplex with less variability 



















4.1.4. Medium exchange at transfection time point 
According to routine the transfection protocol described in ‘Materials and Methods’, cells 
should be prepared one day before transfection (pre-culture), centrifuged and then resuspended 
in fresh medium at transfection time. To determine if these steps are required, CHO-K1 cells 
were pre-cultivated either for one or two days (pre-culture duration) followed by media 
exchanges either in fresh or consumed media (Figure 25) at transfection time.  
 
Figure 25: Efficacy of pre-culture day and media exchange. 
Media exchange for transfection either by fresh or consumed media, 1 or 2 days pre-culture. All 
experiments were done in duplicate. 
The results demonstrate that higher transfection efficiency (TE) was obtained for cells 
resuspended in fresh media within one day of pre-culture, like in the routine transfection 
protocol. Increasing the pre-culture time to two days and resuspending the cells in fresh media 
decreased transfection efficiency by more than 10% compared to one-day pre-culture. The 
decrease in transfection efficiency occurred for those cells resuspended in consumed media 
either one or two days pre-culture compared to those cells resuspended in fresh media. This 
underlines the necessity of resuspending cells in fresh medium within one day of pre-culture. 
Higher viability is related to lower transfection efficiency. This reflects the inverse relationship 
trend between transfection efficiency and viability, which is consistent with the previous 
results. These results suggest that transfection is possible in consumed media after one day pre-
culture, which facilitates easier scale-up of transient gene expression and avoids media 
exchange. Obtaining transfection efficiency of around 60% is acceptable for afterward 
production process. 
Also, it is worth observing here and regarding the previous results, that transfection efficiency 
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4.1.5. Effect of media osmolality on cell growth and transfection efficiency 
To determine if osmolality can improve transfection efficiency without affecting cell growth, 
different media with various applied osmotic pressures ranging from 288 to 334 mOsm Kg-1 
were tested, firstly for cell cultivation as indicated in Appendix Figure 45. The result showed no 
big difference in the maximal cell number achieved or in cell viability; these ranged from 25 to 
24 x106/mL and 98 to 99% respectively for 48 hrs of cultivation in this osmotic stress range. 
The CHOMACS CD media with the same osmotic pressure as noted previously were used for 
transfection of the same amount of cells, pDNA and PEI as in the routine transfection protocol. 
At 5 hpt, one volume of normal medium 288 mOsm Kg-1 was added to all transfected cultures. 
 
 
Figure 26: Effect of media osmolality on transfection. 
Normal media without NaCl addition has an osmotic pressure of around 288 mOsm Kg-1. All experiments 
were done in triplicate. 
Transfection efficiency and viability at 48 hpt as shown in Figure 26 exhibited no big 
differences in percentage. Under various applied osmolality conditions, transfection efficiency 
averaged 72-74% for all media and viability, 74-80%. Increasing osmolality up to 314 mOsm 
kg-1 slightly improved transient transfection efficiency, but with a reduction in viability to 77% 
compared to normal culture media with 288 mOsm kg-1 and 80% viability. Generally, there is 











































































Transfected cell under different levels of osmotic stress





4.1.6. Discussion of transient transfection in CHOMACS CD media 
The medium is one of the most critical factors in the production of recombinant protein from 
high-density transfected suspension cultures 35. Transient transfection depends on the 
cultivation media, which is necessary for cell growth and protein production. But there are 
some media components that inhibit or diminish transfection efficiency. Performing 
transfection in deficient media (transfection media), which comprises 50% of the final 
production medium, followed by feeding of complete media, is the most-used method for the 
transfection 6,123. This strategy has been described in submitted work. In this study, a 
transfection method in CHOMACS CD production media was developed, consistent with a 
recently reported transfection method in production ProCHO-5 media 35. CHOMACS CD 
serum-free medium is better for providing high cell density growth of up to 18 x106 cells/mL 
124. But, what about its transfection capability? Optimal medium composition is necessary for 
transfection and production since only one media type is used. This has the advantage of 
avoiding the need for cell adaptation to newly introduced transfection media or medium 
exchange after transfection, thus maximizing protein productivity. 
Screening media transfection according to Procedure (A) provides an overview on which kinds 
of media are compatible with PEI transfection. Evaluation the same media with Procedure (B) 
exhibits a different level of transfection efficiency, the best of which is for CHOMACS CD 
media. This type of screening strategy, which is carried out in two stages (A & B), has not, to 
our knowledge, so far been used. The most applied method have been published describes how 
a pre-adapted cell culture is used in each media, then transfection is conducted under specific 
transfection condition one time, after which it is decided which media is suitable or not suitable 
for transfection 125. With this method, some types of media will be rejected for PEI transfection, 
although they could indeed be used for transfection by modifying the transfection procedure 
and testing them under different transfection conditions. The transfection screening procedures 
(A&B) in this study make it possible to distinguish the media that support high or low density 
cell growth and transfection and to quickly evaluate them. In addition, conducting screening 
under two transfection conditions is an excellent tool for confirming whether the media support 
transfection or not, particularly for establishing a starting transfection protocol. 
Since the composition of CHOMACS CD and ProCHO-5, like most commercial media, is 
confidential, some complex media are not amenable to high-density transfection due to the 
presence of a high concentration of inhibitory factors 74. Concerning CHOMACS CD, it is 
likely to provide high transfection efficiency and high cell density with few inhibitory factors 




pDNA/PEI transfection is presumably related to the ability to neutralize the positive charge in 
pDNA/PEI polyplex, which limits the arrival of polyplex to the cell surface 54. Efficient 
transfection occurs when the anionic DNA phosphate backbone is neutralized with an excess 
positive charge of PEI to bind with the anionic cell surface charge 79. 
This study found that the post-transfection dilution step does not affect transfection efficiency 
for the time periods 5-20 hpt, consistent with literature, which states that most transfection 
events occur within the first post-transfection period, when 80% of the pDNA/PEI polyplex is 
uptaken 44,84. At 4.5 hpt the pDNA enters the cell nuclei 126. Therefore volumetric upscaling of 
the transfected culture through media dilution by adding up to 1:7 (v/v) in media volume at 5 
hpt is a promising and feasible way to scale up the volume of transfection culture after 
transfection. 
Raising the amount of pDNA from 6 µg to 24 µg and PEI from 30 µg to 45 µg increases 
transfection efficiency from 55% to 65% but also reduces the viability from 96% to 87%. 
However, an inverse relation between transfection efficiency and toxicity has been previously 
reported 127. Thus the balance between viability and transfection efficiency needs to be 
maintained, since high cell viability and growth rate, as well as high transfection efficiency, are 
prerequisites for obtaining high recombinant protein yields 40,52. 
The most crucial step in PEI transfection concentrates the pre-culture cells and resuspends them 
in fresh medium. Wurm and co-workers found that fresh media produces higher transfection 
efficiency than consumed media, the latter which severely reduces transfection efficiency 128. 
Consistent with this the use of consumed medium in transfection is significantly linked to the 
age of the culture. These observations also agree with those reported by Schlaeger et al 129. The 
logically low transfection efficiency derived with consumed media suggests the presence of a 
component that inhibits PEI transfection or the absence of one that is necessary for it. As the 
pre-culture time becomes longer, the presence of this component in the consumed media also is 
longer, thus reducing efficiency of the transfection.  
The addition of sodium chloride (NaCl) increases the culture osmolality, which aids DNA 
delivery 130, especially with conventional transfection methods. The results reported here, 
however, show that addition of NaCl increases media osmolality from 288 to 334 mOsm Kg-1 , 
but neither had a significant effect on transfection efficiency or on total cell number and 
viability. 
Collectively, these findings outline the initial routine in situ transient PEI transfection protocol 





million cells per mL in CHOMACS CD production media. 2) Dilution of transfection culture 
with 1:1 (v/v) of fresh medium at 5 hpt. This initial transfection protocol provides flexibility for 
culture dilution after transfection, either for dilution up to 1:7 (v/v) with fresh media 
(volumetric scale up) or without dilution (which would be better for fed-batch transient 
transfection). Overall, this study observes a transfection efficiency of about 60-70% for CHO-
K1 cell in CHOMACS CD media at 24 µg and 45 µg amount of pDNA and PEI respectively. 
The same PEI transfection reagent solution mediates about 50–60% transfection efficiency for 
CHO-DG44 cells in ProCHO-5 production media 35. A high level of reproducibility in 
performance was also seen; the cell density, transfection efficiency and viability of parallel 





















4.2. Cell parameters for efficient transfection 
For transient recombinant protein expression, it is important to identify the critical parameters 
needed to obtain a reproducible transfection process with constant transfection efficiency. In 
this chapter, several critical parameters were carefully optimized to obtain reproducible and 
high transfection efficiency. These parameters are related to the host cell (which is CHO-K1 
itself) and the conditions of the culture. The variables include the pre-culture cell density, pre-
culture age and cell cycle and cell density at transfection time, which will be analyzed to assess 
the strength of the previously mentioned high-density routine transfection protocol. Each 
variable was tested independently. Pre-culture is designed to prepare cells for transfection. 
4.2.1. Pre-culture cell density 
A culture which is prepared one day (if not specified otherwise) prior to PEI transfection is 
usually called a pre-culture. To determine if the cell density of the pre-culture plays an 
important role for transfection efficiency, three different pre-cultures of CHO-K1 cells in 
CHOMACS CD medium were prepared in shake flasks. During the pre-culture, the cell 
densities were doubled till transfection time as indicated in Figure 27 (1.2, 2.6, 4.0 and 5.3 x106 
cells/mL). The differences in pre-culture cell density were results from variations in initial cell 
inoculum. For transfection, equal cell densities from each pre-culture were prepared and 
transfected according to the routine transfection protocol mentioned in ‘Materials and Methods’ 
in order to investigate the effects of pre-culture cell density. 
 
Figure 27: Effect of pre-culture cell density at transfection time. 
Transfection efficiency and viability depending on different pre-culture cell densities and constant 
transfected cell density. Comparison of transfection efficiency and cell viability were done using one-way 
ANOVA test n=3. Summary of P value; *p<0.05, ** P<0.01 was considered significant and very 
significant, respectively. 
Figure 27 demonstrates that the highest level of transfection efficiency was observed for a pre-










































Pre-culture cell density at transfection time





transfection efficiency (TE%) than for a pre-culture density of 1.2 x106 cells/mL with a highly 
significant difference. In contrast, the viability was significantly higher for the low cell density 
pre-culture of 1.2 x106 cells/mL compared to other condition.  
This increase in viability is related to the low transfection efficiency, while PEI toxicity 
decreased consistent with the previously mentioned results shown in Figure 23. This directly 
indicated cell density of the pre-culture at transfection time is a very important factor for 
efficient gene transfection, particularly in the range tested. From these results, it can be 
concluded that pre-culture cell density over 1.2 x106 cells/mL is necessary for efficient 
transfection. This can be related to the physiological state of the cells. Cell-cell communication 
can trigger transfection. 
4.2.2. Pre-culture age and cell cycle 
In order to evaluate more thoroughly the effect of pre-culture age and cell cycle dependency on 
transfection efficiency and viability, an equal number of CHO-K1 cells were transfected in 
fresh media from the different pre-cultures aging 15, 40 and 63 hrs. The applied pre-culture age 
in routine transfection protocol is 24 hr. 
 
 
Figure 28: Pre-culture age effect on transfection. 
The graph represents the transfection efficiency and viability at 48 hpt, depending on different pre-culture 
ages. All experiments were done in triplicate. 
Analyzing the data from the Figure 28, it is obvious that the highest transfection efficiency was 
observed for a pre-culture age of 15 hrs, after which efficiency decreased proportionally with 
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a significant effect on transfection efficiency. The younger the pre-culture, the higher is the 
transfection efficiency, consistent with the previously obtained results as shown in Figure 25. 
To guarantee that this transfection efficiency effect depends on pre-culture age and not on pre-
culture cell density belonging to longer cultivation times, the cell density of the pre-culture was 
found to be in the range of over 1.2 to 5 x106 cells/mL (compare to Figure 27), while the cell 
density for a 63-hr-old pre-culture was over this tested range. Therefore, the possible reason for 
why a reduction was observed in transfection efficiency of pre-culture 63 hr age. This would 
interrelate not only to culture age but also to cell density effect. 
Further transfection conditions over 63-hrs-old were not conducted with regard to the viability 
issue. Because as the culture gets older, accumulated waste products and housing cells begin to 
deteriorate physiologically, cell viability starts to decrease to less than 99%. It is worth noting 
that in all conducted transfection experiments, the viability of pre-culture at transfection time 
was always over 99%. 
A decrease in viability after transfection not only depends on transfection toxicity but also on 
the physiological state of pre-culture. Further analysis was carried out to explore the 
physiological state (cell viability) as well as cell cycle distribution pre-culture age from 0 to109 
hrs cultivation time.  
 
Figure 29: Pre-culture cell cycle phase and cell growth. 
The graph represents the typical CHO-K1 cell cycle profile and viability of pre-culture within 109 hr 
cultivation time. 
As observed in Figure 29, cells are usually divided into phases as follows; 70% G0/G1 phase, 
21% G2/M phase and 9% S phase. As the cell culture grows, the S phase starts to increase 
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starts to increase inversely to the S phase until 85 hrs. Before the cultivation ends at 109 hrs, the 
G2/M phase decreases as the cell culture moves into its death phase. 
Correlation between the cell cycle phase and transfection efficiency can be observed by 
combining the data in Figure 28 and Figure 29 as follows: the transfection efficiency is 
inversely proportional to the increase in the pre-culture age, from 15 hr to 63 hr, coinciding 
with a decrease in percentage of the cell population in the S phase after a cultivation period of 
15-40 hrs to 63 hrs. Although these results reveal a minor dependency of transfection on cell 
cycle in the range of 15 to 40 hrs of age, conducting transfection after only one day pre-culture 
age is recommended, consistent with the previously reported results from experiments in media 
exchange described in Chapter 4.1. This finding needs further assessment and confirmation, and 

























4.2.3. Cell density at the transfection time point 
We also expect cell density at the time of transfection to be an important parameter in high 
transfection efficiency. Thus cell density at the time of pDNA addition was varied from 4-18 
x106 cells/mL. The response of this parameter corresponds to transfection efficiency and 
viability at 48 hpt, as well as in the statistical analysis illustrated in Figure 30. The amount of 
pDNA and PEI is constant in relation to cell density. 
 
Figure 30: Cell density at transfection point. 
Study on the effect of different cell densities at the time of transfection on transfection efficiency and cell 
viability -48 hpt. 
Data in Figure 30 demonstrate that the highest transfection efficiency can be observed when 
transfection is carried out at a cell density of 10 x106 cells/mL, like in the routine transfection 
protocol. According to the ANOVA test, the difference in transfection efficiency was not 
significant for any of tested cell densities. These results were surprising because the same 
amount of pDNA and PEI did not appear to be a problem for transfected cultures with either a 
low density of 4 million cells or a higher density of 18 million cells per mL. 
The cell viability of all cultures was over 80% except at the lowest cell density transfected. This 
difference was very significantly corresponding to other culture viability variance. Therefore, 
the participation of 4 x106 cells/mL cell density in the routine transfection condition can be 
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responsible for reducing cell viability. Since the cells present at relatively low cell density at 
transfection time disperse more singly than those at high cell density, they come in contact with 
more toxic-free PEI than those at high cell density. Free PEI contributes to 85% of the total PEI 
in the PEI/DNA polyplexes used for transfection and are responsible for cell membrane 
destabilization 131. Reasons for PEI toxicity are not completely clear, while increasing PEI 
concentrations have a deleterious effect on viability 44. 
Although these results suggest that transfection is efficient in the range of 10-18 x106 cells/mL, 
transfection of 10 x106 cells/mL was considered to be the best condition due to a transfection 
efficiency higher than 50% and with viability above 80%, as well as experiment reproducibility 
with low variation. However, also achieving a high level of transfection efficiency with 
minimum toxicity is necessary. Transfection efficiency of approximately 60% with viability of 
80% is a very promising basis from which to start target recombinant protein production. These 
findings also suggest that performing transfection with a higher cell density of up to 18 x106 
cells/mL is the much more feasible approach, as well as being cost-efficient. The cost of 
production can be further reduced by using the same amount of pDNA and PEI with high cell 
density so that the amount of pDNA per cell is also reduced. In addition, this approach will 
extend the range of scale-up transfection culture volume after transfection by more than 1:7 
(v/v) as indicated in Figure 24. 
4.2.4. Discussion of cell parameters for efficient transfection 
The most important parameters for optimal cell transfection are pre-culture cell density and a 
pre-culture age of one day. The initial cell density affects the initial growth rate and monoclonal 
antibody productivity within hybridoma cells 132, and the physiological status of a cell line has 
an impact on PEI transfection 133. Therefore, the communication state would be better for a high 
pre-culture density of up to 5.2 x106 cells/mL than for a lower cell density of 1.2 x106 cells/mL.  
The maximum cell density for high transfection achieved in literature is 5 x106 cells/mL for 
CHO and 20 x106 cells/mL for HEK-293 cells 35,74. This study reports a maximum cell number 
of up to 18 x06 cells/mL for CHO cell transfection. However, very high cell density of up to 50 
x106 cells/mL with high viability can be transfected if the culture disperses well as a single 
suspension cell (data not shown). In contrast to the literature, this study found no effect of cell 
density during transfection for cell densities between 4-18 x106 cells/mL. Transfection of that 
cell range with an equal amount of pDNA and PEI had the same impact on transfection 
efficiency over 50%. Conversely, an increase in cell density can be compensated by increasing 
the PEI:DNA ratio for efficient transfection, because the extent of particle uptake decreases 




regardless of cell density at that range, is the applied amount of pDNA and PEI. These 
constitute transfectable polyplex pDNA/PEI particles sufficient for this cell density. This 
creates an additional important factor called polyplex particle formation 44. 
The transfection efficiency increased with younger pre-culture age and the presence of a high 
cell population in the S cell cycle phase, as indicated for the 15-40-hr age. In agreement with 
this, PEI transfection would be more efficient when performed with cells in the S phase with a 
minimal efficiency at the G1 phase, because of the cellular uptake of polyplexes (80–90%) 
recorded at in the S phase and (5–30%) in the G1 phase 134. Conversely, the transfection 
efficiency of linear PEI polyplexes and electroporation is insensitive to the cell cycle 135. 
Collectively, all these findings demonstrate that transfection efficiency is limited by pre-culture 
cell density, age, and the necessity to concentrate the cells in fresh media. Cell density at 
transfection time provides a deeper understanding of the PEI transfection efficiency. Nowadays 
many conditions affecting efficiency are being identified, in addition to the already-known 
conditions of the routine transfection protocol. These include 1) for efficient transfection, a pre-
culture cell density in the range of 2.6-5.3 x106 cells/mL is required; a further increase in cell 
density was not tested here; 2) a one-day pre-culture age and concentration of the cells in fresh 
media are a crucial step for transfection; 3) A cell density of 10 x106 cells/mL at transfection 
time is optimal for efficient transfection, and a higher cell density of up to 18 x106 cells/mL is 
possible. The reasons why the transfection efficiency achieved in the routine protocol still does 
not exceed 60-70% remain unclear. This study therefore sought further optimization of the 
protocol by applying a design of experiment DoE approach, to explore the interaction between 
the three basic factors (cell, pDNA, and PEI amount) in the transfection process in an effort to 
improve on the previously achieved transfection efficiency percentage.  
Variability in transfection efficiency (TE%) was often observed in independent experiments, 
probably due to the difference in the percentage of the S phase cell population and passages 












4.3. Design of experiment for optimizing transfection performance 
This optimization study investigates the relationship between pDNA, PEI and cell density, and 
their single or combined effects on transfection efficiency. This optimization step is an 
essential prerequisite before proceeding to the target of optimizing TGF-β1 recombinant 
protein expression. A full factorial design of experiment (DoE) approach was applied and 
investigates systematically the impact of these parameters on transfection efficiency. In doing 
so, a central composite circumscribed (CCC) design was used, in which the cell density factor 
was fixed and tested against a wide range of the other parameters in order to improve the 
efficiency of transfection in the routine transfection protocol.  
The study used a nano-tracking analysis (NTA) method to explore the role of particle size 
pDNA/PEI polyplex formation dynamics in the transfection process. These polyplexes result 
from the electrostatic interaction of negatively charged pDNA and positively charged PEI. This 
NTA analysis aims to combine the advantages of these dynamics with transfection efficiency.  
The study implements another recent strategy, namely repeated transient transfection which 
uses a lower amount of pDNA and PEI. This strategy aims to improve transfection efficiency 
and extend the post-transfection period of transient gene expression. 
Finally, the feasibility of scaling-up the transfection volume in the routine transfection protocol 
from 1 mL (as always applied) to 12.5 mL either in a Tubespin bioreactor®50 and shake flasks 
were evaluated. This step will be useful for further TGF-β1 protein production. 
4.3.1. Interaction of main factors influencing transfection efficiency 
In the first DoE setting dealing with viable cell density, the amount of pDNA and PEI was 
studied, these ranging between 7–13 x106 cells/mL, 10–26 µg and 40–60 µg, respectively. The 
full factorial design was adjusted at two levels for each factor, and has four center points in the 
middle of the design space to assess the significance of each effect, as shown in Appendix 
Figure 48. The data for 10 x106 cells/mL (the cell density of interest in routine transfection 
protocol) is presented in a contour plot as shown in Figure 31. This contour represents effect of 
the main factors on transfection efficiency. In these experiments, pDNA, PEI and cell density 





Figure 31: Contour plots of TE with pDNA and PEI amount. 
Contour plots of transfection efficiency against amounts of PEI and pDNA by µg at 1 mL transfection 
volume. Cell density at transfection time was around 10 x106 cells/mL. Transfection efficiency (TE) was 
determined at 48 hpt and represented by a number. 
Figure 31 shows that high transfection efficiency is quite closely linked to a low amount of 
pDNA at 10 µg and PEI at 40 µg, as well as to a high amount of 26 µg and 60 µg for pDNA 
and PEI, respectively. An unexpected result was that the correlation between pDNA, amount of 
PEI, and transfection efficiency was hard to establish through this study.  
An explanation for this might be that the polyplex of pDNA/PEI particles were generated from 
a different combination of pDNA and PEI amount. Although these complexes originated either 
from interactions between the high and low amounts of pDNA-PEI, they could somehow have 
the same biophysical character, which would enable them to exert a similar influence on 
transfection efficiency, ~50%.  
The ployplex biophysical character involves surface charge on the one hand. Particle size, on 
the other hand, is responsible for the formation of transfectable polyplexes. These polyplexes 
interact with the cells electrostatically and non-specifically. Thus, transfection efficiency can be 
strongly influenced by the polyplex particle size formation and concentration. With reference to 
the optimization of transfection efficiency, these results suggest that evaluating the other 
experimental spaces in the upper right-hand corner and lower left-hand corner of contour Figure 
31 might provide more scope for optimal transfection efficiency. In general, since no direct 
relation between pDNA, amount of PEI and transfection efficiency was found here, we 
performed further investigation for an optimal set of conditions. 
















4.3.2. pDNA/PEI polyplex mediates a wide variety of transfection conditions 
As the above contour plots suggest, two transfection conditions called region A and B were 
evaluated as indicated in Figure 32. The experiment conditions with a new range of PEI and 
pDNA amounts were determined using a central composite circumstance design (CCC) as 
described in Appendix Table 9 and 10. Afterwards, using the same DoE approach as described 
in Table 11, area C of Figure 32 was investigated. All experiments were carried out with a fixed 
amount of cells (10 x106 cells/mL) in 1 mL transfection volume diluted with fresh media at 1:1 
(v/v) and 5 hpt. 
 
Figure 32: Identificatin of optimal transfection area by DoE method. 
Different amounts of pDNA interacting with PEI to affect transfection efficiency. Design spaces area A 
and B represent the interaction of large and small amounts of pDNA and PEI respectively and their effect 
on transfection efficiency (TE%). Area C represents the optimal region. The middle point was represented 
by the average of three experiments to validate the DoE design. 
In Figure 32, area A and B reveal that a transfection efficiency (TE) of over 50% was obtained 
when a higher amount of pDNA interacted with a lower amount of PEI. In the same context, a 
transfection efficiency of less than 50% was also exhibited in both areas (A&B) of the design 
space when influenced by a large amount of PEI with a small amount of DNA. Low 
transfection efficiency could be related to a low amount of pDNA, when this amount was too 
small to transfect 10 million cells per mL as in the case of area B, or related to un-transfectable 































To investigate how a pDNA:PEI ratio (amount of PEI/amount of pDNA) is related to 
transfection efficiency, we visualize the relationship in Figure 33 . 
 
Figure 33: Polyplex profile between pDNA:PEI ratio evaluated by GFP-TE. 
The data represented here contains the same information as Figure 32, twisted by the ratio (w/w) 
pDNA:PEI.  
The threshold of 50% was chosen as the limit of acceptable transfection efficiency (TE%) for 
recombinant protein production. The data in Figure 33 corresponds to that threshold and is 
related to a pDNA:PEI (w/w) a ratio between 1:1.3-1.9. These ratios are interrelated with the 
amounts of pDNA and PEI, i.e. 19-32 µg and 31-62 µg respectively. 
Based on these results and previous findings, this study concludes that the size of polyplex 
pDNA/PEI particle formation needs to be considered in a future study. The variance in 
transfection efficiency can be correlated to the diversity in particle size formation resulting 
from the interplay between different amounts of pDNA and PEI.  
Regarding cell viability, these results indicate that transfection efficiency is over 50% with a 
high percent of viability in area B but not in area A (data not shown). Because of this positive 
aspect combined with the use of less pDNA during transfection compared to the area A, it was 
decided to conduct subsequent experiments in area C Figure 32 with the expectation of 
identifying a means of achieving perhaps even 70% transfection efficiency. 
Unexpectedly, the results clearly show there are no large increases in transfection efficiency. 
The data of area C helps to close the gap between the amount of pDNA-PEI interaction with 
cells and high transfection efficiency. This area provides several choices for acceptable 
transfection efficiency from 50%-67% with viability over 80% and disappearance of low 
















































































































These variations in acceptable transfection efficiency originate from the differences in amounts 
of PEI and pDNA interacting with the same amounts of cell. a various interaction amount of 
PEI and pDNA with the same amount of cells. This offers the possibility of selecting any 
combination for further recombinant TGF-β1 protein production later on, since the PEI polymer 
has a property which allows optimal transfection conditions governed by different amounts of 
pDNA and PEI in the same media. This could explain why PEI exerts such a different 
influence, depending on the type of media, as stated in Chapter 4.1. Bearing this aspect in mind, 
no absolute value can be used to achieve optimal transfection conditions mediated by PEI 
regardless of the cell density and media type. 
This DoE study suggested that a threshold exists for a transfection efficiency of between 50-
73%. The power to increase transfection efficiency over 73% seems to be limited to the 
CHOMACS CD medium.  
Further improvements to increase efficiency without deterioration and loss of viability could 
rely on a better understanding of the influence of the polyplex particle size parameter on 
plasmid uptake. Therefore another study based on a nano-particle tracking analysis (NTA) for 
monitoring the particle size of pDNA/PEI polyplex formation was performed, in an attempt to 




4.3.3. Transfection efficiency reproducibility and nano-tracking analysis (NTA) 
Cells at 48 hpt from two transfection conditions were investigated in a flow cytometer to 
determine transfection efficiency and determine the reproducibility of a routine transfection 
assay as shown in Figure 34. These two transfection conditions were chosen because one was 
based on the DoE result at a ratio 1:1.9 with an expectation of high transfection efficiency and 
the other one at 1:1 pDNA:PEI (w/w) with the expectation of low transfection efficiency. A 
tracking particle formation analysis was then performed for both conditions to find the 
difference in dynamic behavior between low and high TE as indicated Figure 35.  
To achieve this, a fixed amount of pDNA was allowed to interact with different amounts of PEI 
to track the particle size of pDNA/PEI polyplex formation. Once PEI was added to the pDNA, 
this polyplex particle formation began and was monitored at different time intervals up to 80 
min, as shown Figure 35. As expected and previously mentioned in Chapter 4.1, most of the 
transfection particle entered the cells within 60 min. Based on this, an 80-min tracking time was 
thought to be enough to monitor the major differences in the dynamics of polyplex particle size 
formation.  
 
Figure 34: Reproducibility of transfection results obtained with a flow cytometer. 
Ten million CHO-K1 cells per mL were transfected with pEGFP-N1 using the amount of pDNA and PEI 
as indicated in the graph. Each condition was tested three times. A representative dot plot with the flow 
cytometer (Accuri 6 model) of normal CHO-K1 cells and GFP-transfected cells is shown. 
As shown in Figure 34 (upper plot), there was an increase in the number of cells that express 
green fluorescence protein (GFP) compared to those in the lower plot. The only difference in 
GFP expression must be regarded as a difference in the amount of PEI between both 





The combination of a high amount of PEI at about 45 µg and the amount of pDNA 24 µg 
yielded a higher transfection efficiency of about 72% (upper plot). This is in comparison to 
14% from the combination of a low amount of PEI 24 µg (lower plot) with the same amount of 
pDNA. The flow cytometric analysis was done referring to the non-transfected culture. 
On the one hand, this indicates that the amount of PEI has a reliable effect on transfection. On 
the other hand, it indirectly indicates that both amounts of applied PEI are able to condense the 
pDNA molecule to transfectable pDNA/PEI polyplex particles, which in turn influenced 
transfection efficiency. Put another way, a higher ratio of pDNA:PEI 1:1.9 (w/w) would 
condense pDNA better than a lower ratio 1:1 (w/w). This strongly suggests that a high ratio 
could induce a higher concentration of transfectable PEI/pDNA polyplex particles that a low 
ratio. An analysis of the dynamics of particle size formation cannot not prove this, however, as 
long as identification of these transfectable polyplex particles are still unknown. 
 
 
Figure 35: The polyplex particle concentration by selectable size class. 
The left-hand side shows the dynamics of particle size concentration by time at a high ratio of pDNA:PEI 
(w/w). The right-hand side shows these dynamics under a low ratio (w/w). 
For correlating dynamical polyplex particle size with GFP transfection efficiency, the graphs in 
Figure 35 demonstrate the concentration of pDNA/PEI polyplex particle size formation by time. 
The interaction of the same pDNA amount with different amounts of PEI produced polyplex 
aggregates of variable sizes >1000 nm within 80 min. On the one hand, the distribution of 
particle size concentration for both conditions (PEI=24 and PEI=45 µg) is nearly the same. On 
the other, the formation dynamics of this particle size relating to the concentration appears 
slightly different. In both conditions, the interaction starts by forming all types of polyplex 




high concentrations compared to low PEI. This aspect was investigated in NTA and with a 
scanning electron microscope (SEM) images. 
This data exhibits a homogeniety in particle size formation order and dissimilarity in the 
dynamics of this particle formation during tracking over 80 min between both conditions. The 
fluctuation in the dynamics of particle formation coincides with size and concentration. This 
fluctuation was higher up and downlinked with a high amount of PEI in the transfection 
condition, as well as high transfection efficiency − and vice versa. This inconsistency with 
regard to particle size formation and concentration results from electrostatic interaction 
(binding and dissociation of polyplex dynamics) and could indicate high transfection efficiency.  
Particle shape is also an interesting parameter that could provide some reason for investigating 
properties of highly transfectable polyplex. NTA analysis gives information about the shape of 
these particles resulting from light scattering, as shown in Figure 36. Regarding the formation 
of polyplex, both previously mentioned conditions show similarity with a spherical structure 
which started smaller after 5 min of interaction then underwent dynamic changes with time, 






Figure 36: Nano-particles pDNA/PEI polyplex visualized by their light scattering. 
The images were obtained from video images taken by a microscope. 
The only difference that can be slightly noticed at 60 min post-interaction is that the mean 
particle size of these polyplex spheroids was about 422 ± 166 nm in the high transfection 
efficiency condition, while it was 560 ± 239 nm for the low transfection condition. Thus 
transfection condition characterized by smaller-sized spheroid polyplex formation would 
positively influence transfection efficiency. The same difference was confirmed in an 
independent experiment by SEM. 
 
Mean size distribution 5 min post-
interacton = 273 nm with SD 105 nm 
Mean size distribution 60 min post-
interacton = 560 nm with SD 239 nm 
Mean size distribution 60 min post-
interacton = 422nm with SD 166 nm 
Mean size distribution 5 min post-
interacton = 338nm with SD 130 nm 
At low ratio 1:1 (w/w) 24µg pDNA:24 µg PEI 





Figure 37: Scanning electron photograph of pDNA/PEI polyplexes. 
These polyplexes result from the interaction between different amounts of pDNA and PEI as indicated in 
above the image. On the left side are scanning electron micrographs of pDNA:PEI (w/w) with a high ratio 
scale bar, 4µm. On the right side are scanning electron micrographs of pDNA:PEI (w/w) at a low ratio 
scale bar, 8µm. 
Micrographs of SEM Figure 37 reveal that an increase in the amount of PEI to the pDNA 
(related to high transfection efficiency) is characterized by smaller single spherical polyplexes 
of between 170 and 230 nm. In the case of an equal amount of pDNA and PEI, most single 
particle sizes are in the range of 260-300 nm. Larger polyplexes were formed due to re-
aggregation of single spheroids within the PEI polymer, creating a branched spherical shape. 
While still unclear whether the presence of polyplex in dispersed single form or aggregated in 
chain form would be more effective for transfection, the spherical morphology of polyplex 
formation seems to have no effect on transfection efficiency. The spherical polyplex was found 
in high and low transfection efficiency.  
4.3.4. Repeated transient transfection 
In order to overcome the transfection efficiency limitation above 73% and prolong the 
production period afterwards, a repeated transient transfection protocol was implemented by 
media exchange and the low amount of pDNA was used only one time (round). The first (1st) 
transfection step was performed under the routine transfection protocol. The transfection 
efficiency at 48 hpt1 was determined. The cells were passaged like a pre-culture and incubated 
for 24 hrs for the second (2nd) transfection. The second transfection was performed like the first 
but with a smaller amount of pDNA and PEI. Using a smaller amount of pDNA and PEI avoids 






Figure 38: Schematic representation of the repeat transient transfection strategy. 
The diagram shows the first (1st) and second (2nd) transfection steps. 
The effect of the repeated transfection strategy on transfection efficiency was investigated as 
shown in Figure 39. 
 
Figure 39: Repeated transient transfection strategy. 
Effects of second transfection step on transfection efficiency and viability. Error bars represent the 
standard deviation from the mean (N=4). Data were analyzed using T-test, and *p<0.05, ** P<0.01 *** 
P<0.001 was considered significant, very significant and highly significant, respectively. 
In comparing the first transfection step and the second, repeated transfection step, transfection 
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transfection point in step two (hpt2) seems to be a similar at about 68% and 70% respectively as 
shown in Figure 39. However, this result contradicts the intention of the second transfection 
step, which was to increase transfection efficiency up to 100%. As expected, the amount of 
pDNA and PEI used produces 38-50% transfection efficiency as tested in a previous procedure 
(B) Chapter 4.1. However, this transfection level does not occur with repeated transfection. 
This could be associated with a ceiling limiting improved transfection above 73%. But the 
second transfection step improves transfection by about 12% compared to the first transfection 
after 120 hpt1.This difference is quite significant and keeps the transfection efficiency high by 
using a smaller amount of pDNA and PEI.  
Importantly, these results demonstrate that the transfection efficiency of the first transfection 
step is not lost completely after 120 hpt1. With a further increase in cultivation to 144 hpt1, 
transfection efficiency starts to decrease for both conditions (data not shown) reflecting the 
need to apply another repeat transfection round. 
On the other hand, the second transfection step was accompanied by a significant increase in 
viability at 48 hpt2 compared to the first transfection step, although the initial pre-culture 
viability at transfection time was 95% and 99%, respectively. This is probably due to the 
toxicity of the higher amount of pDNA and PEI which applied in the first transfection step 
compared to that used in the second transfection step.  
The possible reasons for increases in viability are the time intervals of about 24 hr in the pre-
second transfection culture, which was established between the first transfection 48 hpt cultures 
and the start of second transfection step. The time interval for the culture in fresh media allows 
viability to increase from 89% to 95%. The second reason are smaller amounts of pDNA and 
PEI of about 6 and 30 µg, respectively, that were applied during the second transfection step, 
and which differed from the amounts in first transfection step.  
The repeat transfection strategy requires a smaller amount of pDNA and PEI for a high 
transfection efficiency (70%) combined with high viability (97%) at 48 hpt2; this allows better 
performance in cell growth and protein expression. These features make this repeat transfection 
approach especially attractive for extended protein expression and more suitable for continuous 
transfection culture. The intermediate pre-culture between the first and second transfection step 
helps to enhance cell growth and viability from 89% to 95%. Further work is required on the 
feasibility of performing repeat transfection strategy through direct addition of pDNA and PEI 







4.3.5. Scale-up of transient transfection 
The scalability of transient transfection was investigated using the Tubespin bioreactor®50 and 
shake flasks. A CHOMACS CD media volume of 12.5 mL was suspended with 10 x106 
cells/mL and transfected with 24 µg of pDNA/mL and 45 µg of PEI/mL. At 5 hpt the cultures 
were diluted with an equivalent volume of media. With a 1-mL transfection volume in the 




Figure 40: Transient transfection scale-up in shake flasks and Tubespin bioreactor®50. 
Comparison of transient transfection in a Tubespin bioreactor®50 and shake flasks with 12.5 mL of 
transfected CHO-K1. Transfection efficiency and viability were measured at 48 and 72 hpt. A transfection 
volume of 1 mL was used here as a reference. 
As shown in Figure 40, the transfection efficiency for both cultures at 48 hpt was about 70%, 
similar to that obtained with a volume of 1 mL transfected culture using the routine transfection 
protocol. The reason that viability increased in 1 mL in the Tubespin bioreactor®50 at 72 hpt is 
related to the addition of fresh media. Generally, this experiment successfully evaluated the 
transient transfection scale-up protocol to 12.5 mL in different culture vessels, i.e, the Tubespin 
bioreactor®50 versus to shake flasks. This step is quite necessary for TGF-β1 production and 
















































Scale-up transfection culuture volume from 1 mL to 12.5 mL




4.3.6. Discussion on the DoE to optimize transfection performance 
In the first DoE, the surprising finding was that the highest transfection efficiency was achieved 
by combining the highest amount of pDNA with the highest amount of PEI and vice versa. 
These data suggest that the amount of PEI and pDNA are more important factors than cell 
density, which is consistent with previously findings concerning the tested range of 4-18 
million cell density per mL discussed in Chapter 4.2. Contrary to our observation, Xie et al 44 
report that higher cell densities and higher amounts of PEI and pDNA are important for in situ 
transfection. Higher concentrations of pDNA and cells with lower ratios of PEI:pDNA have 
been shown to have the absolute highest transfection efficiency 136.  
Each media such as Ex-Cell medium or RPMI F68 has only one optimal transfection efficiency 
point achieved by increasing cell density, PEI and pDNA concentrations 137. But our design 
spaces, called areas A, B, and C, assign more-than acceptable transfection efficiency over 50% 
to CHOMACS CD. There is indeed an advantage to using this as the high transfection 
efficiency is also accompanied by increased viability and less pDNA is required to obtain 
optimal transfection efficiency. 
One major concern with the pDNA:PEI (w/w) ratio as related to transfection efficiency is the 
independently on concentrations. However, most with transfection efficiencies over 50% have 
ratios of around 1:1.3-1.9 (w/w), which are related to the combination of the pDNA and PEI 
amounts of 19-32 µg and 31-62 µg, respectively, in 1 mL transfection volume. Thus the precise 
ratio actually depends on the DNA concentration 129.  
Interestingly, transfecting cells using a wide range of pDNA:PEI ratios (w/w) − 1:1.6, 1:1.8, 
1:2.1 and 1:3 − did not significantly affect the expressing cell population of 61%. In agreement 
with this study, other one reported that the highest transfection efficiency of 72% was the same 
for the DNA:PEI ratio of 1:5 and 1:7 44. However, the diversity of PEI transfectability 
properties is discussed in greater detail in the literature. The property which enables PEI 
polymer to display these numerous optimal features originates from the different magnitudes of 
pDNA and PEI ratios (w/w) of in situ interactions, which could explain the diversity of optimal 
PEI transfection conditions among all reported studies. This property could depend on polyplex 
particle size formation between opposite charged pDNA and PEI electrostatic interaction.  
The dissimilarity in the dynamics of these particle formations during tracking over 80 min 
results from the interaction between equal amount of pDNA and different amounts of PEI, 
which is related to a dissimilarity in transfection efficiency of both conditions. Therefore, 
polyplex particles were generated in low ratios, transfecting only 14 ± 2% of the cells and 72 ± 





In addition, NTA and SEM analysis revealed spherically shaped polyplexes with sizes smaller 
than 422 nm and 230 nm, respectively, at 60 min post-polyplex interaction, which would be 
recommended for PEI mediated transfection. 
Zetasizer analysis studies over 60 min have illustrated that 277 to 950 nm small particle size 
formation seems to be responsible for a high transfection efficiency of 72% 44. Recently, a 
study reported that generating positively charged polyplexes with a size range of <100 nm is 
optimal for PEI-mediated transfection 36. 
However, this study highlights an important aspect of the dynamics of small-sized spherical-
shaped polyplex particle formation, which is may be combined with high transfection 
efficiency. A further polyplex dynamic analysis study over all previously mentioned DoE 
experiments is required to prove this concept. 
Transfection efficiency level changes over time post-transfection. After 48 hpt, the level peaks 
at 72 hpt; at 96 hpt, the efficiency returns to a value equal to that recorded at 48 hpt with no 
significant difference as shown in Chapter 4.1. This could be explained by the fact that 
transfected culture consists of 60% transfected cells (GFP+ cells) and 40% non-transfected cells 
(GFP- cells). By the time post-transfection is running, this GFP-cell population will have grown 
faster than the GFP+ cells. Moreover, GFP+ cells lose their episomal pDNA through cell 
division 138,139. Since transfection efficiency depends on the ratio between transfected and non-
transfected cells, this tends to decrease with prolonged post-transfection time. 
Recently repeated transfections had been introduced by Cervera 86 to tackle the problem of 
losing episomal pDNA in the short period after transient transfection of HEK 293 suspension 
cells. They were able to keep viability of HEK-293 cells over 50% and to extend protein 
expression between 192 and 240 hr by several transfection rounds. 
Here the proposed repeat transfection strategy for only one round in CHO-K1 cells was able to 
increase viability from 89 to 95% and transfection efficiency to 70% in comparison to 98% 
viability and 58.6% transfection efficiency in the first transfection step at 120 hpt1. A pre-
culture 24-hr time interval before conducting the second transfection step enables the culture to 
recover viability again.  
Interestingly, this is the first time in this study that a high transfection efficiency of 70% with a 
high viability of 97% was obtained;  in contrast, higher transfection efficiency has been shown 
in the past to be associated with a decrease in cell viability 133. 
Scalability of the routine transient transfection was achieved successfully up to 12.5 mL 
transfection volume and revealed a similarly high transfection efficiency of about 70% with a 




volumes. This finding is in agreement with the reported reproducible and scalable method with 
300 mL reported by Shen 140. Nevertheless, the scalability of our high transfection efficiency 
protocol is restricted by the relatively high pDNA requirement.  
Altogether, this work shows no further improvement with regard to the level of transfection 
efficiency of over 73% that can be achieved for the routine transfection protocol. The same 
transfection efficiency level can be obtained with other combinations of pDNA and PEI 
amounts. This reflects the significance of particle size formation between the pDNA and PEI 
interaction. This factor should be the key element in any transfection process. Moreover, 
choosing a transfection condition to optimize recombinant protein production is another 




























4.4. Transient TGF-ß1 recombinant protein expression 
This study has already described a simple transient transfection procedure in CHOMACS CD 
medium; the pEGFP-N1 plasmid was utilized to evaluate the transfection efficiency. In this 
chapter, the TGF-β1 plasmid is used instead of the pEGFP-N1 plasmid. The objective of the 
experiments and analysis described in this chapter is to express TGF-ß1 in culture supernatant 
for further purification with Twin-Strep-tag® technology. To do so, the purified protein was 
determined and detected using Nanodrop, Western blot assay, and 2D-fluorescence 
spectroscopy. This was followed by the specific quantification of the active TGF-ß1 by 
enzyme-linked immunosorbent assay (ELISA) in order to determine the bioactivity of the 
purified TGF-ß1 in comparison to the commercial one. This was done through a lung A549 cell 
growth inhibition assay. 
4.4.1. Transient production of TGF- β1 in shake flasks 
Based on the efficiency achieved with GFP-transfection mentioned above in the DoE 
experiments, the transfection conditions that achieved the highest transfection efficiency (of 
about 73%) were used here for TGF-β1 production. The pEGFP-N1 plasmid was replaced by 
TGF-β1 plasmid for this purpose. Although there is a difference in size between pEGFP-N1 
plasmid (4.7 kb) shown in Figure 12 and TGF-β1 plasmid (10.7 kb) shown in Figure 15, the 
delivery limitation due to plasmid size was not considered as a discrete factor in this study.  
For transfection, the contents of three shake flasks each with 12.5 mL of CHOMACS CD media 
were mixed with 12.5 x10 million cells based on the above-mentioned scale-up protocol as 
described in Chapter 4.3. TGF-β1 proteins were successfully produced using 17 µg TGF-β1 
plasmid and 38 µg PEI per mL. 
At 72 hpt all cultures were harvested for cell counting, protein purification, and further analysis 
as shown in Appendix Figure 46. This harvest time was determined based on a previous GFP 
transfection study which focussed on finding the best transfection efficiency time. This is in 
agreement with that reported by Cervera 125. Further study to determine the optimal time for 
harvest is required. 
The viability post-transfection was decreased due to PEI toxicity. In general, a transfected cell 
culture with a viability of above 80% is a good indication of the success of the transfection 
process, similar to what occurred with the pEGFP-N1 plasmid. 
The TGF-ß1 purified protein from culture supernatant was detected by applying the reducing 
conditions of the SDS-page protocol, followed by a Western blot of that protein with a TGF-β1 







Figure 41: Evaluation of purified TGF-β1 protein detection by Western blotting. 
Lane 1: shows a protein-size marker. Lane 2: shows commercial TGF-β1. Lane 3: shows the purified 
TGF-β1 from transfected culture supernatant. 
Western blot analysis of the commercial TGF-β1 shown in Lane 2 of Figure 41 shows that the 
upper band is about 75 kDa, which can be assigned to the latent form of TGF-β1. The other 
bands of about 25 kDa and 14 kDa were assigned to the active (mature) TGF-β1-dimer and 
monomer form, respectively. Regarding TGF-β1 purified from culture supernatant, the upper 
band is also assigned to latent-TGF-ß1 fused tag protein, which increased in size at 100 kDa 
compared to the commercial one of about 75 kDa of latent TGF-β1. The second band illustrates 
the mature form at 14 kDa monomer structure, as shown in Figure 41.  
Based on this, the commercial and purified TGF-β1 proteins show a similarity in band size with 
regard to the mature TGF-ß1 monomer form. This data is consistent with the notion that mature 
TGF-β1 can be visualized under non-reducing conditions as a dimer form of 25 kDa and under 
reducing conditions in a monomer form of 12-15 kDa 94,141. However, the difference in band 
size between the latent purified TGF-β1 protein and commercial TGF-β1 were caused by the 
presence of tags in the purified one and the fact that the two proteins originate from different 
CHO cell clones. Latent TGF-β1 can be visualized on the non-reducing Western blot analysis at 
75, 80, 84, 90, or 100 kDa 93,97,142. 
However, the TGF-ß1 plasmid design was intended to produce the monomer form of the mature 





that the cells secrete TGF-ß1 in a latent form (homodimer of latency-associated peptide and 
mature TGF- ß1) and the mature form releases this under acidic conditions 143. This explains 
why both forms are revealed in the membrane of the Western blot analysis in Figure 41. 
The plasmid-produced TGF-ß1 fusion protein is connected to the C-terminal portion with a 
Twin-Strep-tag® 28 amino acid (3 kDa) to enable protein purification to take place 115. At the 
same time, it was connected to the N-terminal portion with a short fluorescence chain to 
monitor protein productivity 111. The fluorescent chain consists of 39 amino acids (4.4 kDa), 
including a tryptophan fluorescent tag plus linker and enterokinase cutting sites, as shown on 
the plasmid map in Figure 15.  
This work demonstrated that the plasmid design is able to synthesize the TGF-β1 in transfected 
CHO-K1. The active TGF-ß1 (mature) was secreted into the supernatant of the transfected 
culture as confirmed by Western blot analysis. A contradictory description appears in the 
literature stating that the folding and secretion of active TGF-β1 requires plasmid directed to the 
expression of the TGF-β1 prodomains 144,145.  
4.4.2. Determining the protein concentration  
Transfection efficiency is not directly measurable for TGF-ß1 protein. Because TGF-ß1 is not 
fluorescent and secretes extracellularly, not intracellularly like GFP, the transfection quality is 
instead detected by the amount of protein produced. The total protein purified by Strep-Tactin® 
Superflow® column in elution buffer fraction E1, E2, and E3 concentration was assessed by 
Nanodrop A280 measurements as shown in Table 4.  









Total amount of 
purified protein  
[µg] 
E1 1.2 mL 510 612 
E2 5.2 mL 170 884 
E3 1 mL 140 140 
Ʃ 7.4 ml  1636 
 
Based on Nanodrop A280 analysis shown in Table 4, the calculation of the volumetric 
productivity of purified TGF-ß1 concentration from the whole culture supernatant (60 mL) is 
about 27 µg/mL (i.e. 27 mg/L). This calculation was made by dividing the total protein amount 
in all elution buffer fractions E1, E2, and E3 by the amount of loaded culture supernatant 
volume in the column. 
To standardize the concentration of purified TGF-ß1 with the commercial TGF-ß1 in order to 




concentration determination by ELISA. This step is required because the intensity of the active 
protein band is relatively much lower than the latent TGF-ß1, as appears in the Western blot 
analysis in Figure 41. Therefore, the concentration of E2 fraction (which represents the main 
fraction) was estimated according to the calibration curve of commercial TGF-β1 using the 
developed indirect ELISA assay as shown in Figure 47 ‘Appendix section’.  
The total volumetric active protein concentration of fraction E2 was about 15 ± 2 ng/mL (i.e. 
0.015 ± 0.002 mg/L), in relation to the total amount of culture supernatant (60 mL). This 
calculation was made as mentioned above. The result shows a big difference between the 
amount of mature and total TGF-ß1 purified from culture supernatant based on this 
determination method. The total TGF-ß1 estimated by Nanodrop is much higher at about 14700 
ng/mL compared to the 15 ng/mL of the mature TGF-ß1, as determined by ELISA. This 
difference seems to be consistent with that band's intensity as indicated by Western blot 
analysis. The latent band shows more intestate than the mature band in the same protein 
fraction. 
However, the literature reports that the maximum volumetric yield of TGF-ß1 produced from 
stable CHO cells cultivated in T-500 triple layer flasks under acid activation was about 26.6 
mg/L of total protein and 10.6 mg/L of mature TGF-ß1. This is based on a determination with a 
bicinchoninic acid assay (BCA assay) and ELISA respectively 94.  
Comparing those findings with our results above, the big difference in active protein 
concentration could be related to the activation process, which allows the liberation of 
biologically active TGF-ß1 from its latent form. This step was not applied in this experiment 
here.  
Most cultured cells generate little, if any, active TGF-β. This may be due to the fact that some 
TGF-β activation occurs at the cell surface 146 and that they generate local mature TGF-β which 
in turn binds to the cell surface receptor and therefore were not detectable at that level. 
It is also worth noting that non-transfected CHO-K1 cells produce natural TGF-β1 in picogram 
amounts, which contaminates the clinical products produced by these cells 147. The ELISA 
determination assay shows the absolute active TGF-β1 concentration. 
4.4.3. Production of TGF-β1 protein through different transfection conditions 
Three experiments were conducted to estimate the optimal transfection conditions for TGF-ß1 
production and to find the correlation between GFP-transfection efficiency (as determined 
previously) and TGF-ß1 protein productivity. Three transfection conditions with different GFP-
transfection efficiency (GFP-TE) as estimated before in Chapter 4.3 are applied here with TGF-





with 12.5 mL of CHOMACS CD media in each were mixed with 12.5 x10 million cells 
followed by 1:1 (v/v) media dilution at 5 hpt as previously mentioned. At 72 hpt all cultures 
were harvested for direct quantification of protein by ELISA as shown in Table 5. The 
purification process was omitted since there was no further need to use pure TGF-ß1.  
Table 5: Estimation of mature TGF-β1 from culture supernatant by ELISA.  
Transfection condition per 10 x106 cells/mL x12.5 mL 
transfection volume  
Concentration of mature-










1 38 17 73 26 ± 1.4 
2 45 24 62 13 ± 2.5 
3 30 6 50 5 ± 1.3 
 
Table 5 shows that different levels of TGF-β1 expression were successfully produced under 
different transfection conditions (1-3). The concentration of TGF-β1 varied according to the 
transfection conditions applied and coincide with GFP-transfection efficiency.  
The volumetric productivity was calculated with 60 mL for each condition (as mentioned 
previously). The TGF-ß1 yields were estimated as 26, 13 and 5 ng/mL linked to respective 73, 
62 and 50% GFP-transfection efficiency. This reflects the direct relation between protein 
production concentration and transfection efficiency, which increases hand in hand. This is 
consistent with the notion that protein yield is directly dependent on transfection efficiency 40. 
However, there was not an equal increase in productivity and transfection efficiency. 
Under the same transfection conditions (1), a difference was noticed between the mature TGF-
ß1 estimated directly in culture supernatant here and that purified in fraction E2 in the previous 
experiment. The concentration was 26 ng/mL in the culture supernatant and about 15 ng/mL in 
the purified fraction E2. This reduction in the protein concentration may be due to the fact that 
other the fractions, E1 and E3 of the mature protein concentration, were not determined. 










4.4.4. Correlating protein concentration using fluorescence spectroscopy 
In this analysis, different concentrations of purified TGF-β1 (E2 fractions) were obtained from 
different cultivation experiments. The quantification method was based on Nanodrop 
measurements and these samples underwent 2D-fluorescent spectroscopy. As shown in Figure 




Figure 42: Excitation and emission spectra of purified TGF-β1 protein. 
The total purified protein concentration in elution buffer (E2) was indicated in the graph as was the 2D-
fluorescence intensity. 
The result from the fluorescence spectra in Figure 42 for different concentrations of purified 
TGF-ß1 protein reveal that the overall fluorescence signal differed significantly. The 
fluorescent intensity was higher with high protein concentration and vice versa. The signal 
intensity was related to Ex/Em 280/350 wavelength corresponding to short-chain fluorescent 
tryptophan tags. Normally, tryptophan fluorescence is excited between 250-300 nm, and the 
resulting emission ranges from 300-400 nm 111. In general, the result here shows that 
fluorescent intensity was directly related to the concentration of the protein loaded.  
In this context, this difference may be related to the tryptophan tag which is able to generate 
stronger signals in higher protein concentrations than in lower ones. This would improve the 
ability of 2-D fluorescence to distinguish the target protein from other proteins in the cell 
culture, in particular at online measurements. Tagged antibodies with short chain tryptophan 
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untagged protein within a maximum (Ex.nm/Em.nm) at 280 nm/350 nm 111. However, this 
aspect needs further investigation, due to the absence of TGF-β1 untagged protein as a 
reference. 
4.4.5. Bioactivity of TGF-ß1 protein test with the A549 cell line 
The purified protein in elution buffer was concentrated with a vivaspin cutting membrane tube 
then resuspended in DEMEM media at various concentrations of 179, 88 and 44 ng/mL as 
determined with ELISA. The equivalent concentration of commercial TGF-β1 was tested in 
parallel as a positive control. For the negative control, the same experiment was performed 
without the addition of TGF-β1. The viable cell proliferation rate of A-549 human lung 
epithelial carcinoma cells (CCL-185) was measured by CellTiter Blue®-Assay. Cell viability 
assay (CTB-Test) as described in the ‘Materials and Methods’ section.  
Figure 43: Bioactivity of TGF-ß1 secreted from transfected CHO-K1 cells. 
Percent changes in A-549 cell proliferation based on TGF-β1 concentration. Data were analyzed using 
two-tailed paired t-test compared to control (N=3), and *p<0.05, ** P<0.01 t-test was considered 
significant and very significant respectively. 
TGF-β1 is a multifunctional growth factor with various effects described in the literature. In 
this experiment, its capacity to inhibit A-549 cell proliferation was tested. The results in Figure 
43 show that the addition of TGF-β1 inhibits the proliferation of A-549 cells compared to the 
negative control (0 ng/mL-TGF-β1). After 5 days of cultivation, the commercial and the 
purified TGF-β1 show a comparable result with regard to the effect on the A-549 cells. The 
increase in this effect is also evident at higher concentrations (compare 44 and 176 ng/mL TGF-
β1). Cultures with concentrations of 88 and 176 ng/mL show a very significantly different 
effect from concentrations of 44 ng/mL. This result indicates that the TGF-ß1 expressed in 




Measurement of TGF-β1 activity is an important step in optimizing productivity before scaling 
up the protein production process. TGF-β1 activity was therefore determined in this study using 
the A549 lung carcinoma CCL-185 cell growth inhibition bioassay via CellTiter Blue®-Assay. 
In agreement with the literature, we observed a decrease in cell viability (indirect indicator for 
cell growth) in CCL-185 in response to increasing TGF-β1 concentration 106. 
The antibody used in ELIZA recognizes only the active form according to the manufacturer’s 
instructions, and TGF-β1 exerts its effect only through the mature (active) dimer form. 
Therefore, it was important to measure the amount of active TGF-β1 in the total purified protein 































Production of recombinant proteins is important for therapeutic and research development 
purposes, both in the lab or on an industrial scale. 
Establishing an efficient method for transient protein expression is a necessary not only for the 
rapid production of these recombinant proteins but also might be interesting for the fast 
screening and isolation of highly productive cell clones in a stable transfection process. The 
transient transfection method depends on a multitude of different factors that have to be 
adjusted to obtain an efficient and reproducible method to transfect cells in a Tubespin 
bioreactor®50 (small scale) or shake flasks (relatively large scale). These factors include 
selecting suitable transfected production media to support high density transfection. 
Determining the ideal post-transfection time is necessary before culture dilution with various 
volumes of media for further volumetric scale-up. Evaluating the scale-up of transfection 
culture is also a necessary step towards production of a desired protein like TGF-ß1. 
Important factors in the transfection protocol include studying the state of cell culture by 
investigating the effect of pre-culture cell density, and resuspending cells in consumed or fresh 
media in parallel with culture age and cell cycle. Such knowledge will increase the protocol 
strength and help avoid variability noise. Testing the transfection protocol with a wide range of 
cell densities at transfection time point, has proved its validity for possible application in 
continuous culture. Plasmid and PEI transfection reagent concentration is a critical factor for 
choosing optimal transfection conditions for protein production. Correlation of pDNA/PEI 
polyplex particle size formation with the transfection efficiency is helpful for understanding the 
role of this physical polyplex property in the transfection process. Implementation of a repeat 
transfection strategy is necessary to extend the post-transfection expression time of proteins.  
For all of these purposes, the goal of this thesis has been to optimize these parameters related to 
media, cells, and transfection polyplex with regard to their influence on transfection efficiency 
and cell viability. This was done either by changing factors one by one or by studying the 
interaction of factors using the design of experiment (DoE) approach.  
The findings of this study with regard to different commercial media were screened for PEI 
compatibility, either at low or at high cell density. The screening study showed that the medium 
CHOMACS CD (well established media for bioprocess development) is suitable for high cell 
density transfection at 10 million cells per mL. The time of diluting this high cell density 
transfected culture after i.e. 5 hours post-transfection (hpt), is critical, while dilution or no 
dilution of the transfected culture volume has no effect on transfection efficiency. In addition, 




consumed media, was also investigated here. This experiment proved that cell collection and 
dispersal in fresh media is a crucial step for transient transfection. Seeking to determine if the 
cell density of the pre-culture that is used afterward for transfection in fresh media has an 
impact on the transfection process, we found that pre-culture at transfection time in the range of 
2.6-5.3 x106 cells/mL provides a good basis for further process optimization of over 60% TE 
and 80% viability. Increasing pre-culture age from 1 day up to 3 days causes a reduction in 
transfection efficiency corresponding slightly with the increase in S phase cell population. The 
presence of NaCl in media at transfection time leads to an increase in osmolality. This is in 
contrast to cell viability below 80% where transfection efficiency remains nearly unchanged. 
The decrease in cell density at transfection time from 10 million cells per mL to 4 million or an 
increase to 18 million had no effect on transfection efficiency. However, the former transfection 
condition leads to a decrease in viability. A high density transfection protocol for 10-18 million 
cells/mL using 24 µg of pDNA and 45 µg PEI enhanced transfection efficiency ~60% with a 
viability of over 80% at 48 hpt, with the dual target strategies of volumetric scale-up and a 
smaller amount of pDNA per cell. 
Using the DoE approach, we were able to identify several conditions for increasing transfection 
efficiency ranging from 50-70%. These conditions were derived from combining various 
amounts of pDNA and PEI, which interact with the same amount of cell material to improve 
transfection efficiency (enlarge the optimal transfection condition range). This offers the 
advantage of using smaller amounts of pDNA and PEI during transfection while at the same 
time increasing transfection efficiency to over 73% and viability to over 80%. This mainly 
reflects the indirect impact on transfectability of polyplex pDNA/PEI particle size formation, a 
factor resulting from a variation in amounts of pDNA and PEI. Tracking the dynamics of 
polyplex formation over 80 min via nano-tracking analysis (NTA), which utilizes a laser light 
scattering microscope. This study explored the dynamics of pDNA/PEI polyplex formation 
between a high transfection efficiency of 70% and a low transfection efficiency of 14%. Both 
transfection conditions resulted from a fixed amount of pDNA combined with different 
amounts of PEI. Although the dynamics of particle size formation, shapes and counts were 
different, the drawback of this analysis is the need to identify transfectable pDNA/PEI polyplex 
to distinguish between both conditions. Because of this, it is hard to elucidate polyplex 
properties and their effect on transfection efficiency. Both transfection conditions can generate 
nano-spherical particles, either singly or in aggregate. Higher concentrations of smaller particle 






One drawback of the previous protocol, however, is its use of relatively high amounts of pDNA 
and PEI. Repeat transient transfection has been shown to be a useful and reliable way to extend 
gene expression time for 120 hpt with a high transfection efficiency of ~70% and viability over 
95%. This was achieved by using a small amount of 6 µg pDNA and 30 µg PEI for 10 million 
cells per mL in the second transfection step. Applying one-day pre-culture period (time 
interval) between the first and second transfection step improved the viability of the transfected 
culture. 
Polyethylenimine (PEI) in situ transient transfection proved to be a simple and successful gene 
transfer method in both the Tubespin®50 bioreactor and in 125-mL shake flask cultivation. The 
central prerequisite for this protocol is the preparation of cells from pre-culture (less than 24 hrs 
of age with a cell density range of 2.6-5.3 x106 cells/mL). These cells are prepared at a high cell 
density of 10-18 x106 cells/mL in fresh media for transfection. In situ transfection by adding 24 
µg pDNA then 45 µg PEI, showed 60 ± 10% green fluorescence protein (GFP) positive cells 
(transfection efficiency) at 48 hpt. 
Scalability is achieved either volumetric through an increase in production volume after five 
hours of transfection (the process is linearly scalable from 1 mL to 8 mL in a Tubespin 
bioreactor®50) or through an increase in transfection culture volume (the process is linearly 
scalable up to 12.5 mL in a Tubespin bioreactor®50 and shake flask).  
Efficient transfection of CHO-K1 cells with TGF-ß1 plasmid tagged by tryptophan and Twin-
Strep-tag® was achieved, based on the progress of the GFP-transient transfection model. The 
transfection condition was obtained using the amount within a shake flask of 17 µg pDNA:38 
µg PEI in CHOMACS CD. The maximum purified TGF-ß1 produced was about 27 mg/L 
compared to 30 mg/L for the highest yields of recombinant TGF-ß1 reported in the literature 94.  
An off-line 2D-fluorescence spectroscopy assay was used to correlate fluorescence signal 
intensity with tryptophan TGF-ß1 tagged protein concentration, which is considered to be a 
reliable tool for future online technical applications. Another plasmid directed to untagged 
TGF-β1 will be useful for seeing the effect of tryptophan tags and to validate its fluorescence 
signal. 
The strength of the fluorescence signal is strongly proportional to the purified TGF-β1 protein 
concentration. 
Finally, the bioactivity of the purified mature TGF-β1 quantified by ELIZA was successfully 
determined with a cell-based bioactivity assay. This shows an excellent level of activity and 
reproducibility, consistent with commercial TGF-ß1. The increase in the TGF-ß1 concentration 
had a strongly inhibitory effect on cell growth in the epithelial lung carcinoma A549 cell line. 
Conclusions and Perspectives 
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6. Conclusions and Perspectives 
In conclusion, a polyetheyleneinimne (PEI) transient transfection procedure makes it easy to 
perform transient protein production on a lab scale using the mammalian CHO-K1 suspension 
cells cultivated in a CHOMACS CD medium. 
The work performed in this thesis contributes to the scientific knowledge not only of transient 
transfection but also with regard to the development of a recombinant protein production 
platform. Interesting new goals were developed in connection with this subject: 
 Transfection CHO-K1 suspension cell density up to 18 million cells/mL of without prior 
preparation of a pDNA/PEI transfection cocktail. 
 The omission of a dilution step after transfection would assist in establishing very high 
density transient transfection for future application with perfusion culture. 
 Overcoming the problem of having to use two types of media, one for transfection and 
the other for production (accepted protocol not published yet and not mentioned here), 
would involve e.g. using only one production media −CHOMACS CD − for transfection 
and cultivation. Transfection and production in a single medium would enhance protein 
productivity, cell growth, up-scaling and GMP compliance because of the lower 
contamination risk and easier handling involved (fewer handling steps). In this context, 
in situ transient transfection is superior to conventional transfection methods, especially 
when performed on a large bioreactor scale. 
 Use of pre-culture one day prior to transfection with cell density between 2.6-5.3 
million cells per mL at transfection time is an important step for efficient transfection, in 
addition to concentrating the cells to ten million cells per mL in fresh media.   
 Use of a minimal amount of 6 µg pDNA:30 µg PEI to achieve 38-50% transfection 
efficiency with a viability of over 90% combined with high standard deviation; it was 
not recommended for use in this study as the first step of transfection, but would be 
preferable to a repeat transfection strategy. 
 Use of a relatively high amount of 24 µg pDNA:45 µg PEI in the routine protocol of the 
first step of transfection elevates the transfection efficiency level to 60-74% with a 
viability of over 80% combined with less standard deviation in independent experiments 
(more stable condition).  
 Study of DoE approach exploring various optimal transfection conditions resulting from 
various amounts of pDNA and PEI interaction under the same cell density, giving an 
opportunity to select low amounts of pDNA-PEI combined with a high level of 
transfection efficiency.  




 Study of a nano-tracking analysis exploring the dynamics of pDNA/PEI polyplex 
formation and correlate this biophysical character with transfection efficiency. The most 
spherical shape in a small size offers the most transfection efficiency. 
In general, one drawback of the transfection protocol in this work has been the need to 
concentrate the cells at high density for large scale transfection, especially with regard to the 
need for large scale culture centrifugation to collect the cells.  
Additional experiments are required to further improve the process: 
 Further scalability of the transient transfection protocol to larger scales such as 600 
shaker bioreactor and 2-liter bioreactor.  
 The omission of a concentrated pre-culture cell step required for obtaining high cell 
density for transfection. Extension of the pre-culture cell density range to reach 10 
million cells per mL at transfection day, followed directly by in situ transfection would 
provide an attractive solution for large-scale transfection, in addition to the use of a cell 
retention device.   
 Characterization of pDNA/PEI polyplex formation correlated to transfection efficiency.   
 Expansion of the results to different mammalian cell types and a cell culture model. 
 Evaluation of the purified TGF-ß1 amino acid sequences by mass spectroscopy analysis. 
 Release of mature TGF-ß1 from latent TGF-ß1 through a protein activation process.  
 Expansion of protein bioactivity results to different cell lines, stem cell differentiation, 
and cell transformation.  
 Optimization TGF-ß1 protein productivity in shake flasks. 
 Use of a fluorescence spectroscopy (bioview) sensor for real-time monitoring of TGF-













Table 6: List of required equipment. 
Devices/Disposables Manufacturer, Country 
Centrifuge microfuge 3s Thermo Fisher Scientific Inc., USA 
Flow cytometer BD Accuri™ C6 BD Biosciences, USA 
Flow Cytometer EPICS XL-MCL Beckmann-Counter, Florida, USA 
Laminar flow hood  Thermo Fisher Scientific Inc., USA 
SDS-PAGE gel system unit Bio-Rad Laboratories Inc., USA  
Shake flasks 125, 250, 1000 mL Corning Inc., USA 
Shaker (DOS-20L) ELMI, North America 
Shaker (SHKR-03 Model DOS-10M) ELMI, North America 
Sterile pipettes 2, 5, 10, 50 mL Corning Inc.,USA 
Strep-Tactin® Superflow® column 1-mL IBA GmbH, Germany 
Tubespin bioreactor®50 TPP, Trasadingen, Switzerland 
Ultra centrifuge Thermo Fisher Scientific Inc., USA 
Vortex Mixer VM-300 NeoLab Migge GmbH, Germany 
Water bath Memmert GmbH, Germany 






















Table 7: List of Chemicals. 
Chemicals  Manufacturer, Country 
Agarose ABgene, Germany 
Ammonium persulfate (APS) Carl Roth GmbH + Co. KG, Germany  
Ampicillin-sodium salt VWR Chemicals, Germany 
Ap conjugate substrate kit Bio-Rad Laboratories Inc., USA 
Bacteriological Agar-Agar Carl Roth GmbH + Co. KG, Germany 
Bromophenol blue  Merck Millipore, Germany 
DNA 10000 bp Ladder Thermo Fisher Scientific, Germany 
Ethanol Merck Millipore, Germany 
Ethylenediaminetetraacetic acid (EDTA) AppliChem GmbH, Germany 
Isopropanol Merck Millipore, Germany 
kanamycin sulfate Carl Roth GmbH + Co. KG, Germany 
Methanol (MeOH) Merck Millipore, Germany 
Monosodium phosphate (NaH2PO4) Merck Millipore, Germany 
penicillin/streptomycin) PAA Laboratories GmbH, Austria 
Prestained ladder 26616 Thermo Fisher Scientific, Germany 
Roti®-Safe Gel Stain Carl Roth GmbH + Co. KG, Germany 
Rotiphorese Gel 40 Carl Roth GmbH + Co. KG, Germany 
Sal1, Not1, Xba1 and Hind III Thermo Fisher Scientific Inc., USA 
Sodium bicarbonate NaHCO3 Merck Millipore, Germany 
sodium chloride (NaCl) Merck Millipore, Germany 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich Corporation, USA 
Sodium hydroxide (NaOH) Fluka Chemie Ag., switzerland 
Tetramethylethylenediamine (TEMED) Thermo Fisher Scientific Inc., USA 
Tween 20 Carl Roth GmbH + Co. KG, Germany 
Yeast Extract.  Carl Roth GmbH + Co. KG, Germany 











7.3. Buffer, Gel and solution preparation 
Agarose gel electrophoresis 50 x TAE running buffer: 242 μL Tris, 57.1 mL acetic acid, 100 
mL EDTA (0.5 M) added into 25 mL ddH2O.  
15% separation gel: 1.8825 ml of rotiphoresis gel 40, 1.4 ml of 1 M Tris (pH 8.8), 1.2175 mL 
of ddH2O, 10 μL of TEMED, 0.5 mL (1%) of SDS, 10 μL (25%) APS.  
6% collecting gel: 0.75 mL of rotiphoresis gel 40, 0.63 ml of 1 M Tris (pH 6.8), 3.77 mL of 
ddH2O, 0.3 (1%) SDS, 10 μL of TEMED, 10 μL of (25%) APS. 
Antibody diluents solution 40 mL: 20 mL block buffer: 20 mL PBST buffer (50:50) 
Ampicillin stock solution:  
100 mg Ampicillin added into 1 mL ddH2O. 
Kanamycin stock solution: 
50 mg Kanamycin added into 1 mL ddH2O. 
 
7.4. Tubespin bioreactor®50 to an orbital shaker in an incubator 
 
Figure 44: Tubespin bioreactor®50 fitted with a filter cap in an orbital shaker. 
The tubes were maintained in racks designed in house with O-ring in the upper part to fit well on the 













7.5. Cell cultivation under different osmotic stress 
 
Figure 45: CHO-K1 cultivation in different osmotic stress. 
The graph shows CHO-K1 cell growth and viability in different osmotic pressure media for 48 hr. The 
cultivation was done to mimic the transfection condition but without transfection. Cells at 10 million cells 
per mL were collected and seeded in 1 mL of each medium with particular osmotic pressure. The 
osmolality of normal media has osmotic pressure of 288 mOsm kg-1. After 5 hour all culture was diluted 








































































Normal culture under different osmotic stress




7.6. Transient expression of TGF-ß1 protein 
All steps which required for TGF-ß1 protein expression starting from pre-culture preparation 
step for 24 hr followed by cell collection at high cell density in fresh media and distributed by 
shaking for one hour. This ended by its transfection with pDNA and PEI amount and diluted by 
1:1 (v/v) for further cultivation at 72 hpt was represented below. 
 
Figure 46: Transfection process for TGF-ß1 production. 
The process is starting with pre-culture cells at low cell density. After that, the cells were duplicated 
within 24 hr. The cells were collected and resuspended in fresh media. For well cell dispersion, the cells 
were cultivated for 1-hour under shaken condition. The cultures were transfected in situ by adding the 
appropriate amount of pDNA and PEI respectively. The cultures were diluted after transfection i.e. 5 hpt 
with equal volume of fresh media. The transfected culture was left of 72 hpt prior to harvest. 
More detailed related to transient transfection process which applied in this study was 
explained in the standard operating procedure (SOP) available in house.  
7.7. Purification of TGF-ß1 protein 
For purifying Twin-Strep-tag® fusion proteins directly from cell culture supernatant, Iba 
protocol was applied by loading the Strep-Tactin® Superflow® column with the total 60 mL of 
transfected culture supernatant at flow rate 1 mL/min. The purification was carried out on the 
basis of the Twin-Strep-tag® fusion protein coupled to Strep-Tactin® affinity chromatography. 
In elution step, the destination protein was collected in the elution buffer. Elution buffer 
fraction with purified protein was quantified by Nanodrop. More detail was explained in SOP 



























































Viabilty % TCC x[10^6 cells/mL]
The typical transient transfection process
Pre-culture duration Collect 10*10^6 cells 
/mL for transfection 
Post transfection hours (pth)






7.8. ELISA calibration 
Various concentration of commercial TGF-ß1 was used to establish the calibration curve below 
through serial dilution method.   
 
Figure 47: Calibration curve of commercial TGF-β1. 
Various concentrations of commercial TGF-β1 were incubated with monoclonal antibody anti TGF-β1. 
After washing with TPBS, the wells were again incubated with peroxidase-labeled anti-mouse IgG. 




















7.9. Designs regions of DoE 












                 
DoE is designed with 4 central points and 8 run distributed as shown in design region Figure 48. 
 
 
















Cell density x106 
[cells/mL] 
1 N1 12 10 40 7 
2 N2 3 26 40 7 
3 N3 1 26 40 13 
4 N4 6 26 60 13 
5 N5 7 26 60 7 
6 N6 11 10 60 7 
7 N7 9 10 60 13 
8 N8 2 10 40 13 
9 N9 8 18 50 10 
10 N10 4 18 50 10 
11 N11 10 18 50 10 















1 N1 5 31 5 
2 N2 8 45 5 
3 N3 7 31 15 
4 N4 6 45 15 
5 N5 11 28 10 
6 N6 10 48 10 
7 N7 1 38 3 
8 N8 9 38 17 
9 N9 2 38 10 
10 N10 4 38 10 
11 N11 3 38 10 
Transfection condition: 10 million cells per mL. At 5 hpt the culture diluted 1:1 (v/v) then at 48 hpt TE% and 
viability were determined. The table illustrates the factor settings required. 










1 N1 11 55 20 
2 N2 7 69 20 
3 N3 8 55 30 
4 N4 10 69 30 
5 N5 4 52 25 
6 N6 5 72 25 
7 N7 2 62 18 
8 N8 3 62 32 
9 N9 6 62 25 
10 N10 1 62 25 
11 N11 9 62 25 
Transfection condition: 10 million cells per mL. At 5 hpt the culture diluted 1:1 (v/v) then at 48 hpt TE% and 













Table 11: Illustrates the factor settings required for (CCC) DoE design of area C. 
Exp No Exp Name: 




1 N1 9 33 21 
2 N2 2 43 21 
3 N3 1 33 27 
4 N4 11 43 27 
5 N5 8 31 24 
6 N6 10 45 24 
7 N7 6 38 20 
8 N8 3 38 28 
9 N9 5 38 24 
10 N10 4 38 24 
11 N11 7 38 24 
Exp No 
Exp Name: 





1 N1 9 31 19 
2 N2 2 45 19 
3 N3 1 31 29 
4 N4 11 45 29 
5 N5 8 28 24 
6 N6 10 48 24 
7 N7 6 38 17 
8 N8 3 38 31 
9 N9 5 38 24 
10 N10 4 38 24 
11 N11 7 38 24 
Transfection condition: 10 million cells per mL. At 5 hpt the culture diluted 1:1 (v/v) then at 48 hpt TE% and 
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